<div id="page0" style="width:595.3pt;height:793.7pt">
<img style="position:absolute;transform:matrix(.3200215,0,-0,.31959314,-34.125337,-11.502014)" src="data:image/jpeg;base64,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">
<p style="top:61.5pt;left:228.2pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">Contents lists available at</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5"> ScienceDirect</span></p>
<p style="top:86.6pt;left:178.7pt;line-height:13.9pt"><span style="font-family:AdvOT596495f2,serif;font-size:13.9pt">Toxicology and Applied Pharmacology</span></p>
<p style="top:117.3pt;left:196.7pt;line-height:8.0pt"><span style="font-family:AdvOT0de51fd2,serif;font-size:8.0pt">journal homepage:</span><span style="font-family:AdvOT0de51fd2,serif;font-size:8.0pt;color:#2a7ca5"> www.elsevier.com/locate/taap</span></p>
<img style="position:absolute;transform:matrix(.3199774,0,-0,.31986577,587.9027,-28.243973)" src="data:image/jpeg;base64,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">
<p style="top:146.2pt;left:37.6pt;line-height:9.6pt"><span style="font-family:AdvOT596495f2,serif;font-size:9.6pt">Invited Review Article</span></p>
<p style="top:165.0pt;left:37.6pt;line-height:13.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:13.4pt">Melatonin&apos;s e</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:13.4pt">&#xfb03;</span><span style="font-family:AdvOT596495f2,serif;font-size:13.4pt">cacy in stroke patients; a matter of dose? A systematic review</span></p>
<p style="top:189.2pt;left:37.6pt;line-height:10.6pt"><span style="font-family:AdvOT596495f2,serif;font-size:10.6pt">Eva Ramos</span><sup><span style="font-family:AdvOT596495f2,serif;font-size:7.5pt;color:#2a7ca5">a</span></sup><sup><span style="font-family:AdvOT596495f2,serif;font-size:7.5pt">,</span></sup><sup><span style="font-family:AdvOT8608a8d1+20,serif;font-size:7.5pt;color:#2a7ca5">&#x204e;</span></sup><span style="font-family:AdvOT596495f2,serif;font-size:10.6pt">, V&#xed;ctor Farr&#xe9;-Alins</span><sup><span style="font-family:AdvOT596495f2,serif;font-size:7.5pt;color:#2a7ca5">b</span></sup><sup><span style="font-family:AdvOT596495f2,serif;font-size:7.5pt">,</span></sup><sup><span style="font-family:AdvOT596495f2,serif;font-size:7.5pt;color:#2a7ca5">c</span></sup><span style="font-family:AdvOT596495f2,serif;font-size:10.6pt">, Javier Egea</span><sup><span style="font-family:AdvOT596495f2,serif;font-size:7.5pt;color:#2a7ca5">b</span></sup><sup><span style="font-family:AdvOT596495f2,serif;font-size:7.5pt">,</span></sup><sup><span style="font-family:AdvOT596495f2,serif;font-size:7.5pt;color:#2a7ca5">c</span></sup><span style="font-family:AdvOT596495f2,serif;font-size:10.6pt">, Francisco L&#xf3;pez-Mu&#xf1;oz</span><sup><span style="font-family:AdvOT596495f2,serif;font-size:7.5pt;color:#2a7ca5">d</span></sup><sup><span style="font-family:AdvOT596495f2,serif;font-size:7.5pt">,</span></sup><sup><span style="font-family:AdvOT596495f2,serif;font-size:7.5pt;color:#2a7ca5">e</span></sup><sup><span style="font-family:AdvOT596495f2,serif;font-size:7.5pt">,</span></sup><sup><span style="font-family:AdvOT596495f2,serif;font-size:7.5pt;color:#2a7ca5">f</span></sup><sup><span style="font-family:AdvOT596495f2,serif;font-size:7.5pt">,</span></sup><sup><span style="font-family:AdvOT596495f2,serif;font-size:7.5pt;color:#2a7ca5">g</span></sup><span style="font-family:AdvOT596495f2,serif;font-size:10.6pt">, Russel J. Reiter</span><sup><span style="font-family:AdvOT596495f2,serif;font-size:7.5pt;color:#2a7ca5">h</span></sup><span style="font-family:AdvOT596495f2,serif;font-size:10.6pt">,</span></p>
<p style="top:202.2pt;left:37.6pt;line-height:10.6pt"><span style="font-family:AdvOT596495f2,serif;font-size:10.6pt">Alejandro Romero</span><sup><span style="font-family:AdvOT596495f2,serif;font-size:7.5pt;color:#2a7ca5">a</span></sup><sup><span style="font-family:AdvOT596495f2,serif;font-size:7.5pt">,</span></sup><sup><span style="font-family:AdvOT8608a8d1+20,serif;font-size:7.5pt;color:#2a7ca5">&#x204e;</span></sup></p>
<p style="top:219.2pt;left:37.6pt;line-height:4.5pt"><span style="font-family:AdvOT596495f2,serif;font-size:4.5pt">a</span><span style="font-family:AdvOT7fb33346.I,serif;font-size:6.4pt"> Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine, Complutense University of Madrid, 28040 Madrid, Spain</span></p>
<p style="top:227.8pt;left:37.6pt;line-height:4.5pt"><span style="font-family:AdvOT596495f2,serif;font-size:4.5pt">b</span><span style="font-family:AdvOT7fb33346.I,serif;font-size:6.4pt"> Health Research Institute, Clinical Pharmacology Service, University Hospital La Princesa, Autonomous University of Madrid, C/ Diego de Le&#xf3;n 62, 28006 Madrid, Spain</span></p>
<p style="top:236.3pt;left:37.6pt;line-height:4.5pt"><span style="font-family:AdvOT596495f2,serif;font-size:4.5pt">c</span><span style="font-family:AdvOT7fb33346.I,serif;font-size:6.4pt"> Institute Te&#xf3;</span><span style="font-family:AdvOT7fb33346.I+fb,serif;font-size:6.4pt">&#xfb01;</span><span style="font-family:AdvOT7fb33346.I,serif;font-size:6.4pt">lo Hernando for Drug I+D, School of Medicine, Autonomous University of Madrid, 28029 Madrid, Spain</span></p>
<p style="top:244.9pt;left:37.6pt;line-height:4.5pt"><span style="font-family:AdvOT596495f2,serif;font-size:4.5pt">d</span><span style="font-family:AdvOT7fb33346.I,serif;font-size:6.4pt"> Faculty of Health Sciences, University Camilo Jos&#xe9; Cela, C/ Castillo de Alarc&#xf3;n 49, 28692 Villanueva de la Ca&#xf1;ada, Madrid, Spain</span></p>
<p style="top:253.4pt;left:37.6pt;line-height:4.5pt"><span style="font-family:AdvOT596495f2,serif;font-size:4.5pt">e</span><span style="font-family:AdvOT7fb33346.I,serif;font-size:6.4pt"> Neuropsychopharmacology Unit, Hospital 12 de Octubre Research Institute (i+12), Avda, C&#xf3;rdoba, s/n, 28041 Madrid, Spain</span></p>
<p style="top:262.0pt;left:37.6pt;line-height:4.5pt"><span style="font-family:AdvOT596495f2,serif;font-size:4.5pt">f</span><span style="font-family:AdvOT7fb33346.I,serif;font-size:6.4pt"> Portucalense Institute of Neuropsychology and Cognitive and Behavioural Neurosciences (INPP), Portucalense University, R. Dr. Ant&#xf3;nio Bernardino de Almeida 541,</span></p>
<p style="top:271.9pt;left:37.6pt;line-height:6.4pt"><span style="font-family:AdvOT7fb33346.I,serif;font-size:6.4pt">4200-072 Porto, Portugal</span></p>
<p style="top:279.1pt;left:37.6pt;line-height:4.5pt"><span style="font-family:AdvOT596495f2,serif;font-size:4.5pt">g</span><span style="font-family:AdvOT7fb33346.I,serif;font-size:6.4pt"> Thematic Network for Cooperative Health Research (RETICS), Addictive Disorders Network, Health Institute Carlos III, MICINN and FEDER, Madrid, Spain</span></p>
<p style="top:287.7pt;left:37.6pt;line-height:4.5pt"><span style="font-family:AdvOT596495f2,serif;font-size:4.5pt">h</span><span style="font-family:AdvOT7fb33346.I,serif;font-size:6.4pt"> Department of Cellular and Structural Biology, UT Health Science Center, San Antonio 78229, TX, USA</span></p>
<p style="top:321.5pt;left:37.6pt;line-height:7.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:7.0pt">A R T I C L E I N F O</span></p>
<p style="top:342.0pt;left:37.6pt;line-height:6.4pt"><span style="font-family:AdvOT7fb33346.I,serif;font-size:6.4pt">Keywords:</span></p>
<p style="top:350.6pt;left:37.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Melatonin</span></p>
<p style="top:359.2pt;left:37.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Stroke</span></p>
<p style="top:367.8pt;left:37.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Systematic review</span></p>
<p style="top:376.3pt;left:37.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Translational doses</span></p>
<p style="top:321.5pt;left:203.1pt;line-height:7.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:7.0pt">A B S T R A C T</span></p>
<p style="top:341.4pt;left:203.1pt;line-height:7.2pt"><span style="font-family:AdvOT596495f2,serif;font-size:7.2pt">There is a lack of e</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:7.2pt">&#xfb00;</span><span style="font-family:AdvOT596495f2,serif;font-size:7.2pt">ective therapies for stroke patients; its treatment is even more di</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:7.2pt">&#xfb03;</span><span style="font-family:AdvOT596495f2,serif;font-size:7.2pt">cult considering the</span></p>
<p style="top:351.0pt;left:203.1pt;line-height:7.2pt"><span style="font-family:AdvOT596495f2,serif;font-size:7.2pt">unexpected onset of the disease. In the last decade, melatonin has emerged as a promising neuroprotective agent</span></p>
<p style="top:360.6pt;left:203.1pt;line-height:7.2pt"><span style="font-family:AdvOT596495f2,serif;font-size:7.2pt">which is able to cross the blood-brain-barrier (BBB) and with a low toxicity pro</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:7.2pt">&#xfb01;</span><span style="font-family:AdvOT596495f2,serif;font-size:7.2pt">le. The aim of this systematic</span></p>
<p style="top:370.1pt;left:203.1pt;line-height:7.2pt"><span style="font-family:AdvOT596495f2,serif;font-size:7.2pt">review was to summarize and critically review clinical and pre-clinical evidence related to melatonin&apos;s e</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:7.2pt">&#xfb00;</span><span style="font-family:AdvOT596495f2,serif;font-size:7.2pt">ec-</span></p>
<p style="top:379.7pt;left:203.1pt;line-height:7.2pt"><span style="font-family:AdvOT596495f2,serif;font-size:7.2pt">tiveness as a stroke treatment. Together with a comparative dose extrapolation with those used in the selected</span></p>
<p style="top:389.2pt;left:203.1pt;line-height:7.2pt"><span style="font-family:AdvOT596495f2,serif;font-size:7.2pt">randomized controlled trials (RCTs), and based on these data to discuss whether the administered doses correlate</span></p>
<p style="top:398.8pt;left:203.1pt;line-height:7.2pt"><span style="font-family:AdvOT596495f2,serif;font-size:7.2pt">with those advisable in human patients. To address this purpose, we performed a systematic review of the</span></p>
<p style="top:408.3pt;left:203.1pt;line-height:7.2pt"><span style="font-family:AdvOT596495f2,serif;font-size:7.2pt">available literature. A total of 529 records were screened with the selecting of six full articles containing RCTs</span></p>
<p style="top:417.9pt;left:203.1pt;line-height:7.2pt"><span style="font-family:AdvOT596495f2,serif;font-size:7.2pt">that met the inclusion/exclusion criteria. The evidence drawn from these six reports was analyzed to identify</span></p>
<p style="top:427.5pt;left:203.1pt;line-height:7.2pt"><span style="font-family:AdvOT596495f2,serif;font-size:7.2pt">remaining gaps, treatment e</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:7.2pt">&#xfb03;</span><span style="font-family:AdvOT596495f2,serif;font-size:7.2pt">cacy, and to suggest future directions. The primary outcome reported was the</span></p>
<p style="top:437.0pt;left:203.1pt;line-height:7.2pt"><span style="font-family:AdvOT596495f2,serif;font-size:7.2pt">reduction of the oxidative response; the secondary outcome was the increase of the survival rate of the patients</span></p>
<p style="top:446.6pt;left:203.1pt;line-height:7.2pt"><span style="font-family:AdvOT596495f2,serif;font-size:7.2pt">in the intervention groups. Calculations derived from animal studies revealed that the translational doses to</span></p>
<p style="top:456.2pt;left:203.1pt;line-height:7.2pt"><span style="font-family:AdvOT596495f2,serif;font-size:7.2pt">humans were substantially higher than those employed in the RCTs. The</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:7.2pt"> &#xfb01;</span><span style="font-family:AdvOT596495f2,serif;font-size:7.2pt">ndings of this systematic review</span></p>
<p style="top:465.7pt;left:203.1pt;line-height:7.2pt"><span style="font-family:AdvOT596495f2,serif;font-size:7.2pt">revealed that there are insu</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:7.2pt">&#xfb03;</span><span style="font-family:AdvOT596495f2,serif;font-size:7.2pt">cient RCTs to prove melatonin&apos;s value in stroke patients. Nevertheless, the evidence</span></p>
<p style="top:475.3pt;left:203.1pt;line-height:7.2pt"><span style="font-family:AdvOT596495f2,serif;font-size:7.2pt">is promising, and further clinical research may support the bene</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:7.2pt">&#xfb01;</span><span style="font-family:AdvOT596495f2,serif;font-size:7.2pt">ts of melatonin in stroke patients, if the</span></p>
<p style="top:484.9pt;left:203.1pt;line-height:7.2pt"><span style="font-family:AdvOT596495f2,serif;font-size:7.2pt">adequate dose is administered.</span></p>
<p style="top:528.1pt;left:37.6pt;line-height:8.0pt"><span style="font-family:AdvOT1efcda3b.B,serif;font-size:8.0pt">1. Introduction</span></p>
<p style="top:549.0pt;left:50.1pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">Among leading worldwide causes of death, stroke is the second and</span></p>
<p style="top:559.5pt;left:37.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">the main cause of disability (</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5">Feigin et al., 2014</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5"> Guzik and Bushnell,</span></p>
<p style="top:569.9pt;left:37.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5">2017</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">). Nevertheless, prevalence and incidence are not easy to interpret</span></p>
<p style="top:580.4pt;left:37.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">due to the lack of available global studies. More prospective studies</span></p>
<p style="top:590.8pt;left:37.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">based on population records worldwide would provide a more reliable</span></p>
<p style="top:601.3pt;left:37.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">epidemiology information. The implementation of such records in all</span></p>
<p style="top:611.7pt;left:37.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">the countries is a di</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:8.0pt">&#xfb03;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">cult task due to costs and time.</span></p>
<p style="top:622.2pt;left:50.1pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">Concerning treatment, stroke has no e</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:8.0pt">&#xfb00;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">ective therapy to prevent</span></p>
<p style="top:632.7pt;left:37.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">brain damage. It is accepted that the recombinant tissue plasminogen</span></p>
<p style="top:643.2pt;left:37.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">activator (tPA) reduces neuronal damage after stroke (</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5">Zivin et al., 1985</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">;</span></p>
<p style="top:653.6pt;left:37.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5">NINDS, 1995</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">). However, a major obstacle is that it should be</span></p>
<p style="top:528.1pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">administered immediately, during a short therapeutic window (3,5 h).</span></p>
<p style="top:538.6pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">Rescuing the ischemic penumbra (adjacent tissue) includes a</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:8.0pt">&#xfb00;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">ording</span></p>
<p style="top:549.0pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">excitotoxicity and disturbed calcium ion homeostasis, mitochondrial</span></p>
<p style="top:559.5pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">failure, oxidative and nitrosative stress, in</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:8.0pt">&#xfb02;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">ammation and apoptosis</span></p>
<p style="top:569.9pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">(</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5">Paschen, 2000</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5"> Chan, 2001</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5"> Iadecola and Alexander, 2001</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5"> Lo et al.,</span></p>
<p style="top:580.4pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5">2005</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5"> Niizuma et al., 2010</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">). There have been several clinically tested</span></p>
<p style="top:590.8pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">drugs that, unfortunately, only modulate one or two of these complex</span></p>
<p style="top:601.3pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">stroke related pathological events.</span></p>
<p style="top:611.7pt;left:319.1pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">Melatonin (</span><span style="font-family:AdvOT7fb33346.I,serif;font-size:8.0pt">N</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">-acetyl-5-methoxytryptamine) is synthesized in mul-</span></p>
<p style="top:622.2pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">tiple cells and organs (</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5">Reiter et al., 2020</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">); its blood cerebrospinal</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:8.0pt"> &#xfb02;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">uid</span></p>
<p style="top:632.7pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">levels are derived from the pineal gland (</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5">Reiter et al., 2014</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">). Melatonin</span></p>
<p style="top:643.2pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">is a multifunctional molecule, mainly known for its regulatory actions</span></p>
<p style="top:653.6pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">of circadian rhythm (</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5">Melo et al., 2017</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">). In most individuals, circulating</span></p>
<p style="top:710.6pt;left:37.6pt;line-height:7.2pt"><span style="font-family:AdvOT596495f2,serif;font-size:7.2pt;color:#2a7ca5">https://doi.org/10.1016/j.taap.2020.114933</span></p>
<p style="top:720.2pt;left:37.6pt;line-height:7.2pt"><span style="font-family:AdvOT596495f2,serif;font-size:7.2pt">Received 4 February 2020; Received in revised form 22 February 2020; Accepted 25 February 2020</span></p>
<p style="top:683.0pt;left:44.0pt;line-height:5.1pt"><span style="font-family:AdvOT8608a8d1+20,serif;font-size:5.1pt">&#x204e;</span><span style="font-family:AdvOT596495f2,serif;font-size:7.2pt"> Corresponding authors.</span></p>
<p style="top:694.1pt;left:49.0pt;line-height:7.2pt"><span style="font-family:AdvOT7fb33346.I,serif;font-size:7.2pt">E-mail addresses:</span><span style="font-family:AdvOT596495f2,serif;font-size:7.2pt;color:#2a7ca5"> eva.ramos@ucm.es</span><span style="font-family:AdvOT596495f2,serif;font-size:7.2pt"> (E. Ramos),</span><span style="font-family:AdvOT596495f2,serif;font-size:7.2pt;color:#2a7ca5"> manarome@ucm.es</span><span style="font-family:AdvOT596495f2,serif;font-size:7.2pt"> (A. Romero).</span></p>
<p style="top:36.2pt;left:203.7pt;line-height:7.2pt"><span style="font-family:CharisSIL,serif;font-size:7.2pt;color:#007faa">Toxicology and Applied Pharm</span></p>
<p style="top:36.2pt;left:302.6pt;line-height:7.2pt"><span style="font-family:CharisSIL,serif;font-size:7.2pt;color:#007faa">acology 392 (2020) 114933</span></p>
<p style="top:729.7pt;left:37.6pt;line-height:7.2pt"><span style="font-family:CharisSIL,serif;font-size:7.2pt">Available online 26 February 2020</span></p>
<p style="top:739.3pt;left:37.6pt;line-height:7.2pt"><span style="font-family:CharisSIL,serif;font-size:7.2pt">0041-008X/ &#xa9;</span></p>
<p style="top:739.3pt;left:84.5pt;line-height:7.2pt"><span style="font-family:CharisSIL,serif;font-size:7.2pt"> 2020 Elsevier Inc. All rights reserved.</span></p>
<img style="position:absolute;transform:matrix(.3111133,0,-0,.3111133,626.40017,179.3865)" src="data:image/png;base64,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">
<p style="top:174.4pt;left:506.5pt;line-height:10.0pt"><span style="font-family:CharisSIL,serif;font-size:10.0pt">T</span></p>


<p style="top:58.8pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">melatonin levels markedly decline with natural aging (</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5">Reiter et al.,</span></p>
<p style="top:69.2pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5">1980</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5"> Reiter et al., 1981</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">) which likely contributes to pathophysiological</span></p>
<p style="top:79.7pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">changes and dysfunctions including stroke (</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5">Fiorina et al., 1996</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">;</span></p>
<p style="top:90.1pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5">Ritzenthaler et al., 2009</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5"> Kitkhuandee et al., 2014a, 2014b</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5"> Reiter et al.,</span></p>
<p style="top:100.6pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5">2014</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">).</span></p>
<p style="top:111.0pt;left:319.1pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">There is a credible evidence of melatonin&apos;s therapeutic value in</span></p>
<p style="top:121.5pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">animal stroke models. Treatment with melatonin in stroke models (mice</span></p>
<p style="top:132.0pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">and rats) reduced infarct size, edema, in</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:8.0pt">&#xfb02;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">ammatory and apoptotic re-</span></p>
<p style="top:142.4pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">sponse, preserved BBB permeability and attenuated oxidative damage</span></p>
<p style="top:152.9pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">among others (</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5">Tables 1, 2</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">).</span></p>
<p style="top:163.4pt;left:319.1pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">When designing clinical trials, especially phase I and phase II, the</span></p>
<p style="top:173.8pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">dose, administration route, and timing are critical points to identify</span></p>
<p style="top:184.3pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">e</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:8.0pt">&#xfb00;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">ective results. From the doses administered in animal models, an</span></p>
<p style="top:194.7pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">appropriate translation to humans it success is necessary to be</span></p>
<p style="top:205.2pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">achieved. The experimental doses should not be only extrapolated by a</span></p>
<p style="top:215.6pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">simple body weight conversion to a human equivalent dose (HED), the</span></p>
<p style="top:226.1pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">body surface area (BSA) should likewise be used as a normalization</span></p>
<p style="top:236.6pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">method (</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5">Reagan-Shaw et al., 2008</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">).</span></p>
<p style="top:247.0pt;left:319.1pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">The overall objectives of the current analyses was to provide a</span></p>
<p style="top:257.5pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">comprehensive review of the evidence for melatonin&apos;s e</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:8.0pt">&#xfb03;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">cacy in the</span></p>
<p style="top:268.0pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">treatment of stroke and to develop translational dose calculations to</span></p>
<p style="top:278.4pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">compare them to doses employed clinically. To date, no systematic</span></p>
<p style="top:288.9pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">review has been published attempting to de</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">ne melatonin&apos;s e</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:8.0pt">&#xfb00;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">ects in</span></p>
<p style="top:299.3pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">stroke patients.</span></p>
<p style="top:320.2pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT1efcda3b.B,serif;font-size:8.0pt">2. Materials and methods</span></p>
<p style="top:341.1pt;left:319.1pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">This review was performed according to the systematic review</span></p>
<p style="top:351.6pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">methodology described in PRISMA guidelines to obtain all the articles</span></p>
<p style="top:362.1pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">that could contain relevant RCTs and information regarding melatonin</span></p>
<p style="top:372.6pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">and stroke to June 20, 2019. We utilized this methodology due to its</span></p>
<p style="top:383.0pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">advantages, such as transparency of the methods and criteria that had</span></p>
<p style="top:393.5pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">been use to select and study the related reports. The following metho-</span></p>
<p style="top:404.0pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">dology was designed and approved by all authors</span><span style="font-family:AdvOT7fb33346.I,serif;font-size:8.0pt"> a priori</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">.</span></p>
<p style="top:424.9pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT7fb33346.I,serif;font-size:8.0pt">2.1. Search strategy</span></p>
<p style="top:445.8pt;left:319.1pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">We develop a systematic search of Medline (</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5">https://www.ncbi.nlm.</span></p>
<p style="top:456.2pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5">nih.gov/pubmed</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">), Scopus (</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5">https://www.scopus.com</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">), web of science</span></p>
<p style="top:466.7pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">(</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5">https://apps.webofknowledge.com</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">) and the Cochrane library (</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5">http://</span></p>
<p style="top:477.2pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5">www.cochranelibrary.com</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">). This search was conducted using the fol-</span></p>
<p style="top:487.6pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">lowing</span></p>
<p style="top:487.6pt;left:339.0pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">terms:</span></p>
<p style="top:487.6pt;left:369.2pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">(melatonin[Title/Abstract])</span></p>
<p style="top:487.6pt;left:475.2pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">AND</span></p>
<p style="top:487.6pt;left:500.2pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">(ischemia[Title/</span></p>
<p style="top:498.1pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">Abstract] OR ischemic[Title/Abstract] OR Stroke[Title/Abstract] OR</span></p>
<p style="top:508.6pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">cerebrovascular accident[Title/Abstract]) AND (Brain[Title/Abstract]</span></p>
<p style="top:519.0pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">OR Cerebral[Title/Abstract]).</span></p>
<p style="top:529.5pt;left:319.1pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">When available, Medical Subject Headings (MESH) terms were</span></p>
<p style="top:539.9pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">used. Reviews were excluded and studies were restricted to those</span></p>
<p style="top:550.4pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">published in English language (June 20, 2019). This search was com-</span></p>
<p style="top:560.8pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">pleted with hand searches.</span></p>
<p style="top:581.7pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT7fb33346.I,serif;font-size:8.0pt">2.2. Study selection</span></p>
<p style="top:602.7pt;left:319.1pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">Search results were exported to EndNote software v X9 (Thomson</span></p>
<p style="top:613.2pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">Reuters) and duplicate publications were automatically or manually</span></p>
<p style="top:623.6pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">removed. Thereafter, eligible articles were selected by reading the title,</span></p>
<p style="top:634.1pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">abstract or full-version when required. Studies were included if they</span></p>
<p style="top:644.5pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">were: RCTs, compared with a control group</span><span style="font-family:AdvOT7fb33346.I,serif;font-size:8.0pt">,</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt"> due to the lack of RCTs</span></p>
<p style="top:655.0pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">numbers of participants, ages and dosage were admitted. Any dis-</span></p>
<p style="top:665.4pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">agreement regarding the selection of the trials were resolved by con-</span></p>
<p style="top:675.9pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">sensus.</span></p>
<p style="top:696.8pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT7fb33346.I,serif;font-size:8.0pt">2.3. Quality assessment of bias of the selected studies</span></p>
<p style="top:717.8pt;left:319.1pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">To assess the methodological quality of the selected studies, the</span></p>
<p style="top:728.2pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">Cochrane Collaboration&apos;s table for assessing risk of bias was used</span></p>
<p style="top:738.7pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">(</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5">Higgins et al., 2011</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">).</span></p>
<p style="top:739.3pt;left:40.9pt;line-height:7.2pt"><span style="font-family:AdvOT1efcda3b.B,serif;font-size:7.2pt">Table 1</span></p>
<p style="top:739.3pt;left:50.6pt;line-height:7.2pt"><span style="font-family:AdvOT596495f2,serif;font-size:7.2pt">Trial characteristics.</span></p>
<p style="top:734.0pt;left:65.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Study</span></p>
<p style="top:654.4pt;left:65.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Country</span></p>
<p style="top:621.5pt;left:65.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Sample size</span></p>
<p style="top:580.8pt;left:65.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Participants</span></p>
<p style="top:502.4pt;left:65.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Age</span></p>
<p style="top:467.5pt;left:65.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Dosage</span></p>
<p style="top:428.7pt;left:65.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Duration</span></p>
<p style="top:365.3pt;left:65.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Comparison</span></p>
<p style="top:286.7pt;left:65.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Outcome</span></p>
<p style="top:734.0pt;left:82.1pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">(</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Fulia et al., 2001</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">)</span></p>
<p style="top:654.4pt;left:82.1pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Italy</span></p>
<p style="top:621.5pt;left:82.1pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">20</span></p>
<p style="top:580.8pt;left:82.1pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Perinatal asphyxia</span></p>
<p style="top:502.4pt;left:82.1pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">newborns</span></p>
<p style="top:467.5pt;left:82.1pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">10 mg/2 h</span></p>
<p style="top:428.7pt;left:82.1pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">1-day single dosage</span></p>
<p style="top:365.3pt;left:82.1pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Placebo</span></p>
<p style="top:286.7pt;left:82.1pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Reduction of MDA and nitrite/nitrate levels</span></p>
<p style="top:734.0pt;left:90.7pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">(</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Aly et al., 2015</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">)</span></p>
<p style="top:654.4pt;left:90.7pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Egypt</span></p>
<p style="top:621.5pt;left:90.7pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">45</span></p>
<p style="top:580.8pt;left:90.7pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Perinatal asphyxia</span></p>
<p style="top:502.4pt;left:90.7pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">newborns</span></p>
<p style="top:467.5pt;left:90.7pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">10 mg/kg</span></p>
<p style="top:428.7pt;left:90.7pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">5 days</span></p>
<p style="top:365.3pt;left:90.7pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Not treated</span></p>
<p style="top:286.7pt;left:90.7pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Reduce oxidative Stress, improve survival rate and neurodevelopmental outcomes</span></p>
<p style="top:734.0pt;left:99.2pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">(</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Dianatkhah et al., 2017</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">)</span></p>
<p style="top:654.4pt;left:99.2pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Iran</span></p>
<p style="top:621.5pt;left:99.2pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">40</span></p>
<p style="top:580.8pt;left:99.2pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Intubated stroke patients</span></p>
<p style="top:502.4pt;left:99.2pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">40</span><span style="font-family:AdvOT596495f2+20,serif;font-size:6.4pt">&#x2013;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">69</span></p>
<p style="top:467.5pt;left:99.2pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">30 mg/day</span></p>
<p style="top:428.7pt;left:99.2pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">2</span><span style="font-family:AdvOT596495f2+20,serif;font-size:6.4pt">&#x2013;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">20 days</span></p>
<p style="top:365.3pt;left:99.2pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Not treated (No Placebo)</span></p>
<p style="top:286.7pt;left:99.2pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Length of ICU stay, and mortality</span></p>
<p style="top:734.0pt;left:107.8pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">(</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Ahmad et al., 2018</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">)</span></p>
<p style="top:654.4pt;left:107.8pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Pakistan</span></p>
<p style="top:621.5pt;left:107.8pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">80</span></p>
<p style="top:580.8pt;left:107.8pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Perinatal asphyxia</span></p>
<p style="top:502.4pt;left:107.8pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">newborns</span></p>
<p style="top:467.5pt;left:107.8pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">10 mg</span></p>
<p style="top:428.7pt;left:107.8pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">single dose</span></p>
<p style="top:365.3pt;left:107.8pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Not treated (No Placebo)</span></p>
<p style="top:286.7pt;left:107.8pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Survival rate</span></p>
<p style="top:734.0pt;left:116.4pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">(</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Grima et al., 2018</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">)</span></p>
<p style="top:654.4pt;left:116.4pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Australia</span></p>
<p style="top:621.5pt;left:116.4pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">33</span></p>
<p style="top:580.8pt;left:116.4pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">TBI</span></p>
<p style="top:502.4pt;left:116.4pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">24</span><span style="font-family:AdvOT596495f2+20,serif;font-size:6.4pt">&#x2013;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">49</span></p>
<p style="top:467.5pt;left:116.4pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">2 mg/day</span></p>
<p style="top:428.7pt;left:116.4pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">4 weeks</span></p>
<p style="top:365.3pt;left:116.4pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Placebo</span></p>
<p style="top:286.7pt;left:116.4pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Sleep quality and e</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:6.4pt">&#xfb03;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">ciency</span></p>
<p style="top:734.0pt;left:125.0pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">(</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Zhao et al., 2018</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">)</span></p>
<p style="top:654.4pt;left:125.0pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">China</span></p>
<p style="top:621.5pt;left:125.0pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">60</span></p>
<p style="top:580.8pt;left:125.0pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Severe carotid stenosis</span></p>
<p style="top:502.4pt;left:125.0pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">50</span><span style="font-family:AdvOT596495f2+20,serif;font-size:6.4pt">&#x2013;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">80</span></p>
<p style="top:467.5pt;left:125.0pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">6 mg/day</span></p>
<p style="top:428.7pt;left:125.0pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">6 days</span></p>
<p style="top:365.3pt;left:125.0pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Placebo and Blank</span></p>
<p style="top:286.7pt;left:125.0pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Regulates in</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:6.4pt">&#xfb02;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">ammation and oxidation biomarkers</span></p>
<p style="top:739.3pt;left:142.0pt;line-height:7.2pt"><span style="font-family:AdvOT596495f2,serif;font-size:7.2pt">Abbreviations: ICU, intensive care unit; MDA = malondialdehyde; TBI, traumatic brain injury.</span></p>
<p style="top:36.9pt;left:37.6pt;line-height:6.4pt"><span style="font-family:AdvOT7fb33346.I,serif;font-size:6.4pt">E. Ramos, et al.</span></p>
<p style="top:36.8pt;left:397.5pt;line-height:6.4pt"><i><span style="font-family:CharisSIL,serif;font-size:6.4pt">Toxicology and Applied Pharm</span></i></p>
<p style="top:36.8pt;left:480.1pt;line-height:6.4pt"><i><span style="font-family:CharisSIL,serif;font-size:6.4pt">acology 392 (2020) 114933</span></i></p>
<p style="top:760.9pt;left:295.8pt;line-height:6.4pt"><span style="font-family:CharisSIL,serif;font-size:6.4pt">2</span></p>


<p style="top:206.4pt;left:50.1pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">For each study the following criteria were assessed (</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5">Table 1</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">):</span></p>
<p style="top:227.3pt;left:39.3pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">1. Selection bias</span></p>
<p style="top:237.7pt;left:49.4pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">o random sequence generation</span></p>
<p style="top:248.2pt;left:49.4pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">o allocation concealment</span></p>
<p style="top:258.7pt;left:39.3pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">2. Performance and detection bias</span></p>
<p style="top:269.2pt;left:49.4pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">o blinding of participants and personnel and outcome assessment</span></p>
<p style="top:279.6pt;left:39.3pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">3. Attrition bias</span></p>
<p style="top:290.1pt;left:49.4pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">o incomplete outcome data</span></p>
<p style="top:300.5pt;left:39.3pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">4. Reporting bias</span></p>
<p style="top:311.0pt;left:49.4pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">o selective outcome reporting</span></p>
<p style="top:321.4pt;left:39.3pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">5. Other biases</span></p>
<p style="top:342.3pt;left:50.1pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">The domains for each study were graded in three di</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:8.0pt">&#xfb00;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">erent cate-</span></p>
<p style="top:352.8pt;left:37.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">gories; low, high or unclear risk of bias, if the domain was considered;</span></p>
<p style="top:363.3pt;left:37.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">adequate, inadequate or insu</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:8.0pt">&#xfb03;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">cient information was available, re-</span></p>
<p style="top:373.7pt;left:37.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">spectively. The classi</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">cation was developed independently by (ER and</span></p>
<p style="top:384.2pt;left:37.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">AR). After classi</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">cation, the overall quality of each study was con-</span></p>
<p style="top:394.7pt;left:37.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">sidered (</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5">Higgins et al., 2011</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">): good (low risk &gt; 2 item), fair (low</span></p>
<p style="top:405.1pt;left:37.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">risk = 2 item), on weak (low risk for &lt; 2 item). The</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:8.0pt"> &#xfb01;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">nal scores were</span></p>
<p style="top:415.6pt;left:37.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">discussed by all the authors.</span></p>
<p style="top:441.2pt;left:37.6pt;line-height:8.0pt"><span style="font-family:AdvOT1efcda3b.B,serif;font-size:8.0pt">3. Results</span></p>
<p style="top:462.1pt;left:37.6pt;line-height:8.0pt"><span style="font-family:AdvOT7fb33346.I,serif;font-size:8.0pt">3.1. Selection and identi</span><span style="font-family:AdvOT7fb33346.I+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvOT7fb33346.I,serif;font-size:8.0pt">cation of relevant studies</span></p>
<p style="top:483.0pt;left:50.1pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">After electronic and manual literature searches of the mentioned</span></p>
<p style="top:493.4pt;left:37.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">databases, 529 studies were initially obtained. 13 duplicates that were</span></p>
<p style="top:503.9pt;left:37.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">not automatically excluded by EndNote X9 were manually removed.</span></p>
<p style="top:514.3pt;left:37.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">From the 516 records screened, 395 were irrelevant and 115 were an-</span></p>
<p style="top:524.8pt;left:37.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">imal studies. Finally, six studies were included for analysis. A detailed</span></p>
<p style="top:535.3pt;left:37.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2+fb,serif;font-size:8.0pt">&#xfb02;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">ow chart of the selection process is represented in</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5"> Fig. 1</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">.</span></p>
<p style="top:560.8pt;left:37.6pt;line-height:8.0pt"><span style="font-family:AdvOT7fb33346.I,serif;font-size:8.0pt">3.2. Characteristics of studies</span></p>
<p style="top:581.8pt;left:50.1pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">The main characteristics of the studies included are summarized in</span></p>
<p style="top:592.2pt;left:37.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5">Table 1</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">. The selected RCTs showed a wide variation, with regard to age</span></p>
<p style="top:602.7pt;left:37.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">of participants, study design, and measured outcome. Overall, 3 articles</span></p>
<p style="top:613.2pt;left:37.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">included newborns and 3 adults. The dosages ranged from 10 mg to</span></p>
<p style="top:623.6pt;left:37.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">30 mg, administered in a single dose or during several days (from 2 to</span></p>
<p style="top:634.1pt;left:37.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">28 days) after the diagnosis. Most of the studies included a placebo</span></p>
<p style="top:644.5pt;left:37.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">group, the exceptions were newborns where the comparison was made</span></p>
<p style="top:655.0pt;left:37.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">with a non-treated group of subjects.</span></p>
<p style="top:665.4pt;left:50.1pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">A variety of the study outcomes was also conditioned by the parti-</span></p>
<p style="top:675.9pt;left:37.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">cipants age. Newborns were treated when perinatal asphyxia occurred</span></p>
<p style="top:686.4pt;left:37.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">and the main outcome measured was the improvement of the survival</span></p>
<p style="top:696.8pt;left:37.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">rate and the reduction of oxidative damage.</span></p>
<p style="top:707.3pt;left:50.1pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">The summary of the risk of bias is depicted in</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5"> Table 2</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">. It was ela-</span></p>
<p style="top:717.8pt;left:37.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">borated using the Cochrane collaboration tool to describe quality as-</span></p>
<p style="top:728.2pt;left:37.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">sessment and risk of bias on di</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:8.0pt">&#xfb00;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">erent quality domains for each study.</span></p>
<p style="top:738.7pt;left:37.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">All of them present a low risk of attrition and reporting bias. One study</span></p>
<p style="top:483.8pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">(</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5">Dianatkhah et al., 2017</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">) was classi</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">ed as having a high risk of selec-</span></p>
<p style="top:494.3pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">tion and performance bias, despite the use a randomization method, the</span></p>
<p style="top:504.7pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">allocation sequence was not concealed and personnel were not blinded.</span></p>
<p style="top:515.2pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">When there was insu</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:8.0pt">&#xfb03;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">cient information for judging each domain, it</span></p>
<p style="top:525.6pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">was classi</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">ed as unclear risk of bias. The overall quality of the RCTs</span></p>
<p style="top:536.1pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">was good.</span></p>
<p style="top:560.8pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT7fb33346.I,serif;font-size:8.0pt">3.3. Comparative doses</span></p>
<p style="top:581.7pt;left:319.1pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">There are numerous preclinical studies that include melatonin</span></p>
<p style="top:592.2pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">treatment in stroke models. Findings of these studies frequently docu-</span></p>
<p style="top:602.7pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">mented that melatonin was highly e</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:8.0pt">&#xfb00;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">ective in improving post-ischemic</span></p>
<p style="top:613.2pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">damage (</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5">Ramos et al., 2017</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">).</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5"> Table 3</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt"> summarizes melatonin&apos;s e</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:8.0pt">&#xfb00;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">ect on</span></p>
<p style="top:623.6pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">animal stroke models. As summarized, these studies showed that mel-</span></p>
<p style="top:634.1pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">atonin administration was routinely e</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:8.0pt">&#xfb00;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">ective in counteracting several</span></p>
<p style="top:644.5pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">stroke outcomes in animals. One of the most common observations was</span></p>
<p style="top:655.0pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">the e</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:8.0pt">&#xfb03;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">cacy of melatonin in reducing infarct size (</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5">Giusti et al., 1996b</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">;</span></p>
<p style="top:665.4pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5">Uz et al., 1996</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5"> Sinha et al., 2001</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5"> Pei et al., 2003</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5"> Kilic et al., 2004a,</span></p>
<p style="top:675.9pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5">2005a, 2005b</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5"> Lee et al., 2004</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5"> Koh, 2008c</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5"> Chen et al., 2009</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">) and, as a</span></p>
<p style="top:686.4pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">neuroprotectant, by improving neuronal survival and neurogenesis and</span></p>
<p style="top:696.8pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">reducing mortality (</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5">Giusti et al., 1996a</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5"> Sinha et al., 2001</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5"> Kilic et al.,</span></p>
<p style="top:707.3pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5">2004b</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5"> Kilic et al., 2005a, 2005b</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5"> Hung et al., 2008</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5"> Kilic et al., 2008</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">;</span></p>
<p style="top:717.8pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5">Koh, 2008a, 2008b, 2008c</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5"> Koh, 2012</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5"> Juan et al., 2014</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5"> Kim and Lee,</span></p>
<p style="top:728.2pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5">2014</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5"> Paredes et al., 2015</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">). Several studies additionally showed that</span></p>
<p style="top:738.7pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">melatonin reduced BBB hyperpermeability (</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5">Chen et al., 2006</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5"> Jang</span></p>
<p style="top:59.4pt;left:37.6pt;line-height:7.2pt"><span style="font-family:AdvOT1efcda3b.B,serif;font-size:7.2pt">Table 2</span></p>
<p style="top:68.9pt;left:37.6pt;line-height:7.2pt"><span style="font-family:AdvOT596495f2,serif;font-size:7.2pt">Quality assessment of included studies based on Cochrane guidelines.</span></p>
<p style="top:83.9pt;left:43.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Study</span></p>
<p style="top:83.9pt;left:110.8pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Random sequence</span></p>
<p style="top:92.4pt;left:110.8pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">generation</span></p>
<p style="top:83.9pt;left:173.7pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Allocation</span></p>
<p style="top:92.4pt;left:173.7pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">concealment</span></p>
<p style="top:83.9pt;left:236.1pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Blinding of participants,</span></p>
<p style="top:92.4pt;left:236.1pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Personnel and outcome</span></p>
<p style="top:101.0pt;left:236.1pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">assessment</span></p>
<p style="top:83.9pt;left:333.9pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Incomplete</span></p>
<p style="top:92.4pt;left:333.9pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">outcome data</span></p>
<p style="top:83.9pt;left:396.3pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Selective outcome</span></p>
<p style="top:92.4pt;left:396.3pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">reporting</span></p>
<p style="top:83.9pt;left:455.1pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Other bias</span></p>
<p style="top:83.9pt;left:492.1pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Score</span></p>
<p style="top:83.9pt;left:514.9pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Overall</span></p>
<p style="top:92.4pt;left:514.9pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">quality</span></p>
<p style="top:117.5pt;left:43.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">(</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Fulia et al., 2001</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">)</span></p>
<p style="top:117.5pt;left:110.8pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">+</span></p>
<p style="top:117.5pt;left:173.7pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">+</span></p>
<p style="top:117.5pt;left:236.1pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">?</span></p>
<p style="top:117.5pt;left:333.9pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">+</span></p>
<p style="top:117.5pt;left:396.3pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">+</span></p>
<p style="top:117.5pt;left:455.1pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">+</span></p>
<p style="top:117.5pt;left:492.1pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">5</span></p>
<p style="top:117.5pt;left:514.9pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">GOOD</span></p>
<p style="top:126.0pt;left:43.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">(</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Aly et al., 2015</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">)</span></p>
<p style="top:126.0pt;left:110.8pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">+</span></p>
<p style="top:126.0pt;left:173.7pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">?</span></p>
<p style="top:126.0pt;left:236.1pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">?</span></p>
<p style="top:126.0pt;left:333.9pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">+</span></p>
<p style="top:126.0pt;left:396.3pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">+</span></p>
<p style="top:126.0pt;left:455.1pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">+</span></p>
<p style="top:126.0pt;left:492.1pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">4</span></p>
<p style="top:126.0pt;left:514.9pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">GOOD</span></p>
<p style="top:134.6pt;left:43.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">(</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Dianatkhah et al.,</span></p>
<p style="top:143.2pt;left:55.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">2017</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">)</span></p>
<p style="top:134.6pt;left:110.8pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">+</span></p>
<p style="top:134.6pt;left:173.7pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2+20,serif;font-size:6.4pt">&#x2013;</span></p>
<p style="top:134.6pt;left:236.1pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2+20,serif;font-size:6.4pt">&#x2013;</span></p>
<p style="top:134.6pt;left:333.9pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">+</span></p>
<p style="top:134.6pt;left:396.3pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">+</span></p>
<p style="top:134.6pt;left:455.1pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">?</span></p>
<p style="top:134.6pt;left:492.1pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">3</span></p>
<p style="top:134.6pt;left:514.9pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">GOOD</span></p>
<p style="top:151.7pt;left:43.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">(</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Ahmad et al., 2018</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">)</span></p>
<p style="top:151.7pt;left:110.8pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">+</span></p>
<p style="top:151.7pt;left:173.7pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">+</span></p>
<p style="top:151.7pt;left:236.1pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">?</span></p>
<p style="top:151.7pt;left:333.9pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">+</span></p>
<p style="top:151.7pt;left:396.3pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">+</span></p>
<p style="top:151.7pt;left:455.1pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">+</span></p>
<p style="top:151.7pt;left:492.1pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">5</span></p>
<p style="top:151.7pt;left:514.9pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">GOOD</span></p>
<p style="top:160.3pt;left:43.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">(</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Grima et al., 2018</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">)</span></p>
<p style="top:160.3pt;left:110.8pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">+</span></p>
<p style="top:160.3pt;left:173.7pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">+</span></p>
<p style="top:160.3pt;left:236.1pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">+</span></p>
<p style="top:160.3pt;left:333.9pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">+</span></p>
<p style="top:160.3pt;left:396.3pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">+</span></p>
<p style="top:160.3pt;left:455.1pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">+</span></p>
<p style="top:160.3pt;left:492.1pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">6</span></p>
<p style="top:160.3pt;left:514.9pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">GOOD</span></p>
<p style="top:168.9pt;left:43.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">(</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Zhao et al., 2018</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">)</span></p>
<p style="top:168.9pt;left:110.8pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">+</span></p>
<p style="top:168.9pt;left:173.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">+</span></p>
<p style="top:168.9pt;left:236.1pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">+</span></p>
<p style="top:168.9pt;left:333.9pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">+</span></p>
<p style="top:168.9pt;left:396.3pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">+</span></p>
<p style="top:168.9pt;left:455.1pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">+</span></p>
<p style="top:168.9pt;left:492.1pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">6</span></p>
<p style="top:168.9pt;left:514.9pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">GOOD</span></p>
<p style="top:186.1pt;left:37.6pt;line-height:7.2pt"><span style="font-family:AdvOT596495f2,serif;font-size:7.2pt">Key: + low risk of bias;</span><span style="font-family:AdvOT596495f2+22,serif;font-size:7.2pt"> &#x2212;</span><span style="font-family:AdvOT596495f2,serif;font-size:7.2pt"> High risk of bias;? Unclear risk of bias.</span></p>
<img style="position:absolute;transform:matrix(.31996907,0,-0,.31973879,59.18268,-76.15869)" src="data:image/jpeg;base64,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">
<p style="top:460.3pt;left:383.6pt;line-height:7.2pt"><span style="font-family:AdvOT1efcda3b.B,serif;font-size:7.2pt">Fig. 1.</span><span style="font-family:AdvOT596495f2,serif;font-size:7.2pt"> PRISMA</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:7.2pt"> &#xfb02;</span><span style="font-family:AdvOT596495f2,serif;font-size:7.2pt">ow diagram.</span></p>
<p style="top:36.9pt;left:37.6pt;line-height:6.4pt"><span style="font-family:AdvOT7fb33346.I,serif;font-size:6.4pt">E. Ramos, et al.</span></p>
<p style="top:36.8pt;left:397.5pt;line-height:6.4pt"><i><span style="font-family:CharisSIL,serif;font-size:6.4pt">Toxicology and Applied Pharm</span></i></p>
<p style="top:36.8pt;left:480.1pt;line-height:6.4pt"><i><span style="font-family:CharisSIL,serif;font-size:6.4pt">acology 392 (2020) 114933</span></i></p>
<p style="top:760.9pt;left:295.8pt;line-height:6.4pt"><span style="font-family:CharisSIL,serif;font-size:6.4pt">3</span></p>


<p style="top:739.3pt;left:68.4pt;line-height:7.2pt"><span style="font-family:AdvOT1efcda3b.B,serif;font-size:7.2pt">Table 3</span></p>
<p style="top:739.3pt;left:78.1pt;line-height:7.2pt"><span style="font-family:AdvOT596495f2,serif;font-size:7.2pt">Comparative doses of animal studies HED extrapolation dose with clinical trials.</span></p>
<p style="top:734.0pt;left:93.2pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Animal model</span></p>
<p style="top:686.0pt;left:93.2pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Ref</span></p>
<p style="top:542.8pt;left:93.2pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Findings</span></p>
<p style="top:327.8pt;left:93.2pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Days of treatment</span></p>
<p style="top:269.0pt;left:93.2pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Melatonin daily dose</span></p>
<p style="top:269.0pt;left:101.7pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">(mg/kg)</span></p>
<p style="top:191.0pt;left:93.2pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Daily HED for a 70 kg</span></p>
<p style="top:191.0pt;left:101.7pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">adult</span></p>
<p style="top:120.8pt;left:93.2pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Clinical trials daily</span></p>
<p style="top:120.8pt;left:101.0pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">dose</span><span style="font-family:AdvOT596495f2,serif;font-size:4.5pt;color:#2a7ca5"> a</span></p>
<p style="top:734.0pt;left:118.2pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Mice</span></p>
<p style="top:686.0pt;left:118.2pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">(</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Kilic et al., 2005a</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">)</span></p>
<p style="top:542.8pt;left:118.2pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Reduced infarct size and the impairment of survival-promoting cell</span></p>
<p style="top:542.8pt;left:126.8pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">signaling (PI3K/Akt pathway)</span></p>
<p style="top:327.8pt;left:118.2pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">1</span></p>
<p style="top:269.0pt;left:118.2pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">4</span></p>
<p style="top:191.0pt;left:118.2pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">19 mg</span></p>
<p style="top:120.8pt;left:118.2pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">2,6,30 mg</span></p>
<p style="top:686.0pt;left:135.3pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">(</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Kilic et al., 2005b</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">)</span></p>
<p style="top:542.8pt;left:135.3pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Reduced infarct size (30</span><span style="font-family:AdvOT596495f2+20,serif;font-size:6.4pt">&#x2013;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">35%). Restored Akt activity.</span></p>
<p style="top:686.0pt;left:143.9pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">(</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Kilic et al., 2004a</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">)</span></p>
<p style="top:542.8pt;left:143.9pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Reduced infarct size (30</span><span style="font-family:AdvOT596495f2+20,serif;font-size:6.4pt">&#x2013;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">35%). Tissue protection improving vasodilation</span></p>
<p style="top:542.8pt;left:152.5pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">by inhibiting ECE-1</span></p>
<p style="top:686.0pt;left:161.0pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">(</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Kilic et al., 2008</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">)</span></p>
<p style="top:542.8pt;left:161.0pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Improved neuronal survival and enhanced neurogenesis. Promoted motor</span></p>
<p style="top:542.8pt;left:169.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">and coordination de</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:6.4pt">&#xfb01;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">cits recovery.</span></p>
<p style="top:327.8pt;left:161.0pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">29</span></p>
<p style="top:734.0pt;left:178.1pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Mice</span></p>
<p style="top:686.0pt;left:178.1pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">(</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Chen et al., 2006</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">)</span></p>
<p style="top:542.8pt;left:178.1pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Reduced postischemic oxidative and nitrosative damage and preserved</span></p>
<p style="top:542.8pt;left:186.8pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">BBB integrity.</span></p>
<p style="top:327.8pt;left:178.1pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">1</span></p>
<p style="top:269.0pt;left:178.1pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">5</span></p>
<p style="top:191.0pt;left:178.1pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">24 mg</span></p>
<p style="top:734.0pt;left:195.3pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Rats</span></p>
<p style="top:686.0pt;left:195.3pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">(</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Pei et al., 2003</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">)</span></p>
<p style="top:542.8pt;left:195.3pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Reduced the infarct size.</span></p>
<p style="top:327.8pt;left:195.3pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">1</span></p>
<p style="top:269.0pt;left:195.3pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">5</span></p>
<p style="top:191.0pt;left:195.3pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">48 mg</span></p>
<p style="top:686.0pt;left:203.9pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">(</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Koh, 2008c</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">)</span></p>
<p style="top:542.8pt;left:203.9pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Reduced the infarct size. Prevents cell death (</span><span style="font-family:AdvOT7fb33346.I,serif;font-size:6.4pt">via</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt"> NOS regulation).</span></p>
<p style="top:686.0pt;left:212.4pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">(</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Hung et al., 2008</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">)</span></p>
<p style="top:542.8pt;left:212.4pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Reduced brain damage, brain edema and hemorrhagic transformation.</span></p>
<p style="top:686.0pt;left:221.0pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">(</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Koh, 2008a</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">)</span></p>
<p style="top:542.8pt;left:221.0pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Prevents cell death (mediated by the activation of Raf/MEK/ERK/p90RSK</span></p>
<p style="top:542.8pt;left:229.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">cascade).</span></p>
<p style="top:686.0pt;left:238.1pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">(</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Koh, 2012</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">)</span></p>
<p style="top:542.8pt;left:238.1pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Neuroprotection by preventing glutamate related cell damage.</span></p>
<p style="top:686.0pt;left:246.7pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">(</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Pei and Cheung, 2004</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">) (</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Lee et al., 2007</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">)</span></p>
<p style="top:542.8pt;left:246.7pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Ameliorated in</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:6.4pt">&#xfb02;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">ammatory response.</span></p>
<p style="top:686.0pt;left:255.3pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">(</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Juan et al., 2014</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">)</span></p>
<p style="top:542.8pt;left:255.3pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Enhanced long-term neuroprotection, neuroplasticity, and brain</span></p>
<p style="top:542.8pt;left:263.9pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">remodeling.</span></p>
<p style="top:686.0pt;left:272.4pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">(</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Lee et al., 2004</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">)</span></p>
<p style="top:542.8pt;left:272.4pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Reduced cortical and striatal infarct sizes. Enhanced electrophysiological</span></p>
<p style="top:542.8pt;left:281.0pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">and neurobehavioral.</span></p>
<p style="top:686.0pt;left:289.5pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">(</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Chen et al., 2009</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">)</span></p>
<p style="top:542.8pt;left:289.5pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Reduced brain infarct size. Improves functional and electrophysiological</span></p>
<p style="top:542.8pt;left:298.1pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">recoveries.</span></p>
<p style="top:686.0pt;left:306.7pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">(</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Koh, 2008b</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">)</span></p>
<p style="top:542.8pt;left:306.7pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Neuroprotection mediated by Akt activation and FKHR phosphorylation</span></p>
<p style="top:542.8pt;left:315.2pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">(anti-apoptotic signaling pathway).</span></p>
<p style="top:686.0pt;left:323.8pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">(</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Dehghan et al., 2013</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">)</span></p>
<p style="top:542.8pt;left:323.8pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Reduced brain edema, BBB permeability and intracranial pressure, but</span></p>
<p style="top:542.8pt;left:332.4pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">increases veterinary coma scale after TBI</span></p>
<p style="top:327.8pt;left:323.8pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">4</span></p>
<p style="top:734.0pt;left:341.0pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Rats</span></p>
<p style="top:686.0pt;left:341.0pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">(</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Kondoh et al., 2002</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">)</span></p>
<p style="top:686.0pt;left:349.5pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">(</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Torii et al., 2004</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">)</span></p>
<p style="top:542.8pt;left:341.0pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Reduced edema formation in the cerebral cortex and in the striatum.</span></p>
<p style="top:327.8pt;left:341.0pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">2</span></p>
<p style="top:269.0pt;left:341.0pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">6</span></p>
<p style="top:191.0pt;left:341.0pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">57 mg</span></p>
<p style="top:734.0pt;left:358.1pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Mice</span></p>
<p style="top:686.0pt;left:358.1pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">(</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Kilic et al., 2004b</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">)</span></p>
<p style="top:542.8pt;left:358.1pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Increased neuronal survival and decreased disseminate cell injury.</span></p>
<p style="top:327.8pt;left:358.1pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">1</span></p>
<p style="top:269.0pt;left:358.1pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">8</span></p>
<p style="top:191.0pt;left:358.1pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">38 mg</span></p>
<p style="top:734.0pt;left:366.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Mice</span></p>
<p style="top:686.0pt;left:366.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">(</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Alluri et al., 2016</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">)</span></p>
<p style="top:542.8pt;left:366.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Protected against BBB hyperpermeability after TBI.</span></p>
<p style="top:327.8pt;left:366.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">1</span></p>
<p style="top:269.0pt;left:366.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">10</span></p>
<p style="top:191.0pt;left:366.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">48 mg</span></p>
<p style="top:686.0pt;left:375.2pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">(</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Yang et al., 2015</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">)</span></p>
<p style="top:542.8pt;left:375.2pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Reduced mitochondrial oxidative damage.</span></p>
<p style="top:734.0pt;left:383.8pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Rats</span></p>
<p style="top:686.0pt;left:383.8pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">(</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Giusti et al., 1996a</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5"> Giusti et al., 1996b</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5"> Uz</span></p>
<p style="top:686.0pt;left:392.4pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">et al., 1996</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5"> Floreani et al., 1997</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">)</span></p>
<p style="top:542.8pt;left:383.8pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Reduced neuronal injury, behavioural and biochemical disturbances.</span></p>
<p style="top:542.8pt;left:392.4pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Signi</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:6.4pt">&#xfb01;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">cantly reduced mortality.</span></p>
<p style="top:542.8pt;left:401.0pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Prevented neurotoxic e</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:6.4pt">&#xfb00;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">ects of ROS.</span></p>
<p style="top:327.8pt;left:383.8pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">1</span></p>
<p style="top:269.0pt;left:383.8pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">10</span></p>
<p style="top:191.0pt;left:383.8pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">95 mg</span></p>
<p style="top:686.0pt;left:409.5pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">(</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Paredes et al., 2015</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">)</span></p>
<p style="top:542.8pt;left:409.5pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Ameliorated in</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:6.4pt">&#xfb02;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">ammatory and apoptotic response.</span></p>
<p style="top:686.0pt;left:418.1pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">(</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Ozacmak et al., 2009</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">)</span></p>
<p style="top:542.8pt;left:418.1pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Reduced oxidative stress in neurons and improved hippocampal neuronal</span></p>
<p style="top:542.8pt;left:426.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">integrity.</span></p>
<p style="top:327.8pt;left:418.1pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">14</span></p>
<p style="top:734.0pt;left:435.2pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Mice</span></p>
<p style="top:686.0pt;left:435.2pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">(</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Kim and Lee, 2014</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">)</span></p>
<p style="top:542.8pt;left:435.2pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Suppresses apoptosis of hippocampal neurons</span></p>
<p style="top:327.8pt;left:435.2pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">3</span></p>
<p style="top:269.0pt;left:435.2pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">30</span></p>
<p style="top:191.0pt;left:435.2pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">143 mg</span></p>
<p style="top:734.0pt;left:443.8pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Rats</span></p>
<p style="top:686.0pt;left:443.8pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">(</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Jang et al., 2012</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">)</span></p>
<p style="top:542.8pt;left:443.8pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Attenuated BBB disruption,</span><span style="font-family:AdvOT7fb33346.I,serif;font-size:6.4pt"> via</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt"> inhibition of MMP-9 activity.</span></p>
<p style="top:327.8pt;left:443.8pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">3</span></p>
<p style="top:269.0pt;left:443.8pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">100</span></p>
<p style="top:191.0pt;left:443.8pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">955 mg</span></p>
<p style="top:734.0pt;left:452.4pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Rats</span></p>
<p style="top:686.0pt;left:452.4pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">(</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Deykun et al., 2011</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">)</span></p>
<p style="top:542.8pt;left:452.4pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Improved functional outcome in animals.</span></p>
<p style="top:327.8pt;left:452.4pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">1</span></p>
<p style="top:734.0pt;left:460.9pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Rats</span></p>
<p style="top:686.0pt;left:460.9pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">(</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Sinha et al., 2001</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">)</span></p>
<p style="top:542.8pt;left:460.9pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Reduced oxidative damage, ischemic lesion, and improved neurological</span></p>
<p style="top:542.8pt;left:469.5pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">recovery.</span></p>
<p style="top:327.8pt;left:460.9pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">1</span></p>
<p style="top:269.0pt;left:460.9pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">40</span></p>
<p style="top:191.0pt;left:460.9pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">382 mg</span></p>
<p style="top:269.0pt;left:469.5pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">80</span></p>
<p style="top:191.0pt;left:469.5pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">764 mg</span></p>
<p style="top:269.0pt;left:478.1pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">160</span></p>
<p style="top:191.0pt;left:478.1pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">1527 mg</span></p>
<p style="top:734.0pt;left:492.0pt;line-height:5.1pt"><span style="font-family:AdvOT596495f2,serif;font-size:5.1pt">a</span><span style="font-family:AdvOT596495f2,serif;font-size:7.2pt"> Clinical doses used in the selected clinical trials. Abbreviations: Akt, Protein kinase B; BBB, blood brain barrier; ECE-1, endothelin converting enzyme-1; ERK, extracellular signal-regulated kinase; FKHR, forkhead</span></p>
<p style="top:739.3pt;left:504.7pt;line-height:7.2pt"><span style="font-family:AdvOT596495f2,serif;font-size:7.2pt">transcription factor Foxo1; HED, human equivalent dose; MEK, mitogen-activated protein kinase; MMP-9, matrix metalloproteinase 9; NOS, nitric oxide synthase; p90RSK, p90 ribosomal S6 kinase; Raf, proto-oncogene</span></p>
<p style="top:739.3pt;left:514.2pt;line-height:7.2pt"><span style="font-family:AdvOT596495f2,serif;font-size:7.2pt">serine/threonine-protein kinase; ROS, reactive oxygen species; TBI, traumatic brain injury.</span></p>
<p style="top:36.9pt;left:37.6pt;line-height:6.4pt"><span style="font-family:AdvOT7fb33346.I,serif;font-size:6.4pt">E. Ramos, et al.</span></p>
<p style="top:36.8pt;left:397.5pt;line-height:6.4pt"><i><span style="font-family:CharisSIL,serif;font-size:6.4pt">Toxicology and Applied Pharm</span></i></p>
<p style="top:36.8pt;left:480.1pt;line-height:6.4pt"><i><span style="font-family:CharisSIL,serif;font-size:6.4pt">acology 392 (2020) 114933</span></i></p>
<p style="top:760.9pt;left:295.8pt;line-height:6.4pt"><span style="font-family:CharisSIL,serif;font-size:6.4pt">4</span></p>


<p style="top:58.8pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5">et al., 2012</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5"> Dehghan et al., 2013</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5"> Alluri et al., 2016</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">), vascular pro-</span></p>
<p style="top:69.2pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">cesses (</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5">Kondoh et al., 2002</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5"> Kilic et al., 2004a</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5"> Hung et al., 2008</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">),</span></p>
<p style="top:79.7pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">ameliorated the in</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:8.0pt">&#xfb02;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">ammatory response (</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5">Pei and Cheung, 2004</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5"> Lee</span></p>
<p style="top:90.1pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5">et al., 2007</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">) and reduced the degree of oxidative/nitrosative damage</span></p>
<p style="top:100.6pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">(</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5">Giusti et al., 1996a</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5"> Floreani et al., 1997</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5"> Sinha et al., 2001</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5"> Kondoh</span></p>
<p style="top:111.0pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5">et al., 2002</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5"> Torii et al., 2004</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5"> Chen et al., 2006</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5"> Ozacmak et al., 2009</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">;</span></p>
<p style="top:121.5pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5">Yang et al., 2015</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">). These bene</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">cial e</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:8.0pt">&#xfb00;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">ects were apparent following</span></p>
<p style="top:132.0pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">cerebral ischemia/reperfusion and were accompanied by an improve-</span></p>
<p style="top:142.4pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">ment of functional outcomes as well (</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5">Giusti et al., 1996b</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5"> Sinha et al.,</span></p>
<p style="top:152.9pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5">2001</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5"> Lee et al., 2004</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5"> Kilic et al., 2008</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5"> Chen et al., 2009</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5"> Deykun</span></p>
<p style="top:163.4pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5">et al., 2011</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">).</span></p>
<p style="top:173.8pt;left:319.1pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5">Table 4</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt"> indicates that melatonin treatment in newborn animal</span></p>
<p style="top:184.3pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">stroke models was also very e</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:8.0pt">&#xfb00;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">ective. Perinatal brain injury is asso-</span></p>
<p style="top:194.7pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">ciated mainly with in</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:8.0pt">&#xfb02;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">ammation, hypoxia-ischemia (HI) and formation</span></p>
<p style="top:205.2pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">of free radicals. Several studies indicate the e</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:8.0pt">&#xfb03;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">cacy of this neuro-</span></p>
<p style="top:215.6pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">hormone in attenuating cell death and brain injury thereby improving</span></p>
<p style="top:226.1pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">neuromorphophysiology (</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5">Welin et al., 2007</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5"> Carloni et al., 2008</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">;</span></p>
<p style="top:236.6pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5">Alonso-Alconada et al., 2012</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5"> Robertson et al., 2013</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">). It was usually</span></p>
<p style="top:247.0pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">assumed that the antioxidant pro</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">le of melatonin was responsible of</span></p>
<p style="top:257.5pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">this protective e</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:8.0pt">&#xfb00;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">ect against brain injury since there was a reduction in</span></p>
<p style="top:268.0pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">oxidative damage (</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5">Tutunculer et al., 2005</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5"> Signorini et al., 2009</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">;</span></p>
<p style="top:278.4pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5">Balduini et al., 2012</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">). Neonatal HI encephalopathy a</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:8.0pt">&#xfb00;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">ects the ma-</span></p>
<p style="top:288.9pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">turation of the auditory pathway; melatonin preserves functional in-</span></p>
<p style="top:299.3pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">tegrity of the auditory pathway by reducing ROS damage (</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5">Revuelta</span></p>
<p style="top:309.8pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5">et al., 2016</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">). The neuroprotective e</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:8.0pt">&#xfb00;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">ect of melatonin, furthermore,</span></p>
<p style="top:320.2pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">involves the attenuation of endoplasmic reticulum (ER) stress after</span></p>
<p style="top:330.7pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">neonatal HI (</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5">Carloni et al., 2014</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">). The in</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:8.0pt">&#xfb02;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">ammatory response is also</span></p>
<p style="top:341.2pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">ameliorated after melatonin administration in HI rat models (</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5">Welin</span></p>
<p style="top:351.6pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5">et al., 2007</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5"> Villapol et al., 2011</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5"> Balduini et al., 2012</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">).</span></p>
<p style="top:362.1pt;left:319.1pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">In the associated clinical trials, outcomes are not as positive after</span></p>
<p style="top:372.6pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">melatonin administration as in preclinical studies. As shown in</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5"> Table 4</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">,</span></p>
<p style="top:383.0pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">in newborn perinatal asphyxia animal models, even though the studies</span></p>
<p style="top:393.5pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">were RCTs, melatonin showed a good protective pro</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">le; in the animal</span></p>
<p style="top:404.0pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">models the outcomes where much more e</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:8.0pt">&#xfb00;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">ective. This apparent dis-</span></p>
<p style="top:414.4pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">crepancy may be due to a low dosage of melatonin used in human</span></p>
<p style="top:424.9pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">newborns. Additionally, it should be noted that, chronologically, the</span></p>
<p style="top:435.3pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">development of normal sleep rhythm coincides with circadian varia-</span></p>
<p style="top:445.8pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">tions in melatonin levels from the third to sixth month of life (</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5">Arendt,</span></p>
<p style="top:456.2pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5">2006</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">). In humans, after birth, the</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:8.0pt"> &#xfb01;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">rst circadian rhythm of pineal</span></p>
<p style="top:466.7pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">melatonin synthesis and secretion occurs between the sixth and eighth</span></p>
<p style="top:477.2pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">week of life (</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5">Seron-Ferre et al., 2001</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">). Obviously, a number of mole-</span></p>
<p style="top:487.6pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">cular processes remain to be explored relative to melatonin&apos;s e</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:8.0pt">&#xfb03;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">cacy as</span></p>
<p style="top:498.1pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">a stroke treatment.</span></p>
<p style="top:508.6pt;left:319.1pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">When we extrapolated e</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:8.0pt">&#xfb00;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">ective animal doses to humans, the results</span></p>
<p style="top:519.0pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">ranged from 25 to 100 mg, while the administered dose in the newborns</span></p>
<p style="top:529.5pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">was 10 mg. In the animal models, equivalent doses calculated ranged</span></p>
<p style="top:539.9pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">from 5- to 15-fold greater than the administered in RCTs. Human</span></p>
<p style="top:550.4pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">equivalent doses calculated for adults were also signi</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">cantly greater</span></p>
<p style="top:560.8pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">than the administered in the RCTs. To better understand, we summar-</span></p>
<p style="top:571.3pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">ized and compared in</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5"> Table 5</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt"> the melatonin outcomes reported in the 6</span></p>
<p style="top:581.8pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">RCTs (see</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5"> Table 1</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">) and in the animal model studies (reported in</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5"> Tables</span></p>
<p style="top:592.2pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5">3 and 4</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">).</span></p>
<p style="top:613.2pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT1efcda3b.B,serif;font-size:8.0pt">4. Discussion</span></p>
<p style="top:634.1pt;left:319.1pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">This is the</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:8.0pt"> &#xfb01;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">rst systematic review that provides a comprehensive</span></p>
<p style="top:644.5pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">analysis of the evidence regarding the e</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:8.0pt">&#xfb00;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">ectiveness of melatonin in</span></p>
<p style="top:655.0pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">stroke patients. We found six RCTs which met the criterion and which</span></p>
<p style="top:665.4pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">evaluate</span></p>
<p style="top:665.4pt;left:344.0pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">the</span></p>
<p style="top:665.4pt;left:362.7pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">therapeutic</span></p>
<p style="top:665.4pt;left:410.5pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">melatonin</span></p>
<p style="top:665.4pt;left:453.7pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">e</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:8.0pt">&#xfb00;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">ects</span></p>
<p style="top:665.4pt;left:483.9pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">in</span></p>
<p style="top:665.4pt;left:498.4pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">stroke</span></p>
<p style="top:665.4pt;left:527.5pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">patients.</span></p>
<p style="top:675.9pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">Furthermore, we developed a comparative extrapolation of the doses</span></p>
<p style="top:686.4pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">used in RCTs to consider whether these correlate to the doses that</span></p>
<p style="top:696.8pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">would likely be e</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:8.0pt">&#xfb00;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">ective in human patients.</span></p>
<p style="top:707.3pt;left:319.1pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">To date, only six RCTs studied melatonin as a therapeutic agent in</span></p>
<p style="top:717.8pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">stroke or asphyxiated patients (</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5">Fulia et al., 2001</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5"> Aly et al., 2015</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">;</span></p>
<p style="top:728.2pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5">Dianatkhah et al., 2017</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5"> Ahmad et al., 2018</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5"> Grima et al., 2018</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5"> Zhao</span></p>
<p style="top:738.7pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5">et al., 2018</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">). Among them, three involved in newborns (</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5">Fulia et al.,</span></p>
<p style="top:739.3pt;left:40.9pt;line-height:7.2pt"><span style="font-family:AdvOT1efcda3b.B,serif;font-size:7.2pt">Table 4</span></p>
<p style="top:739.3pt;left:50.6pt;line-height:7.2pt"><span style="font-family:AdvOT596495f2,serif;font-size:7.2pt">Comparative doses of newborn animal model studies to HED extrapolation dose with clinical trials.</span></p>
<p style="top:734.0pt;left:65.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Animal model</span></p>
<p style="top:686.0pt;left:65.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Ref</span></p>
<p style="top:595.0pt;left:65.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Findings</span></p>
<p style="top:350.1pt;left:65.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Days of treatment</span></p>
<p style="top:291.2pt;left:65.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Melatonin daily dose (mg/</span></p>
<p style="top:291.2pt;left:74.2pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">kg)</span></p>
<p style="top:205.7pt;left:65.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Daily HED for a 2,5 kg</span></p>
<p style="top:205.7pt;left:74.2pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">newborn</span></p>
<p style="top:121.4pt;left:65.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Clinical trials daily</span></p>
<p style="top:121.4pt;left:73.4pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">dose</span><span style="font-family:AdvOT596495f2,serif;font-size:4.5pt;color:#2a7ca5">a</span></p>
<p style="top:734.0pt;left:90.7pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">7-day-old rats</span></p>
<p style="top:686.0pt;left:90.7pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">(</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Carloni et al., 2008</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">)</span></p>
<p style="top:595.1pt;left:90.7pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Attenuated brain injury and had long-lasting bene</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:6.4pt">&#xfb01;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">ts.</span></p>
<p style="top:350.1pt;left:90.7pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">3</span></p>
<p style="top:291.2pt;left:90.7pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">5 or 15</span></p>
<p style="top:205.7pt;left:90.7pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">25 or 75 mg</span></p>
<p style="top:121.4pt;left:90.7pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">10 mg</span></p>
<p style="top:686.0pt;left:99.2pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">(</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Tutunculer et al., 2005</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">)</span></p>
<p style="top:595.1pt;left:99.2pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Protected against ROS.</span></p>
<p style="top:350.1pt;left:99.2pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">1</span></p>
<p style="top:291.2pt;left:99.2pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">10 or 20</span></p>
<p style="top:205.7pt;left:99.2pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">50 or 100 mg</span></p>
<p style="top:686.0pt;left:107.8pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">(</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Carloni et al., 2014</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">)</span></p>
<p style="top:595.1pt;left:107.8pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Attenuated of ER stress.</span></p>
<p style="top:350.1pt;left:107.8pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">1</span></p>
<p style="top:291.2pt;left:107.8pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">15</span></p>
<p style="top:205.7pt;left:107.8pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">75 mg</span></p>
<p style="top:686.0pt;left:116.4pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">(</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Alonso-Alconada et al.,</span></p>
<p style="top:686.0pt;left:125.0pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">2012</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">)</span></p>
<p style="top:595.1pt;left:116.4pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Reduced cell death, white matter demyelination, and reactive gliosis.</span></p>
<p style="top:686.0pt;left:133.5pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">(</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Balduini et al., 2012</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">)</span></p>
<p style="top:595.1pt;left:133.5pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Reduced OS, in</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:6.4pt">&#xfb02;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">ammation, and glial cells activation in cerebral cortex.</span></p>
<p style="top:686.0pt;left:142.1pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">(</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Revuelta et al., 2016</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">)</span></p>
<p style="top:595.1pt;left:142.1pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Reduced oxidative damage. Preserved functional integrity of the auditory pathway.</span></p>
<p style="top:686.0pt;left:150.7pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">(</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Signorini et al., 2009</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">)</span></p>
<p style="top:595.1pt;left:150.7pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Reduced oxidative damage.</span></p>
<p style="top:686.0pt;left:159.2pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">(</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Villapol et al., 2011</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">)</span></p>
<p style="top:595.1pt;left:159.2pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Did not reduce cortical infarct volume, strongly reduced in</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:6.4pt">&#xfb02;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">ammation and promoted</span></p>
<p style="top:595.1pt;left:167.8pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">myelination in the white matter.</span></p>
<p style="top:350.1pt;left:159.2pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">1</span></p>
<p style="top:291.2pt;left:159.2pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">20</span></p>
<p style="top:205.7pt;left:159.2pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">100 mg</span></p>
<p style="top:686.0pt;left:176.3pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">(</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Welin et al., 2007</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">)</span></p>
<p style="top:595.1pt;left:176.3pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Attenuated cell death and the in</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:6.4pt">&#xfb02;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">ammatory response.</span></p>
<p style="top:734.0pt;left:190.2pt;line-height:5.1pt"><span style="font-family:AdvOT596495f2,serif;font-size:5.1pt">a</span><span style="font-family:AdvOT596495f2,serif;font-size:7.2pt"> Clinical doses used in the selected clinical trials. Abbreviations: ER, endoplasmic reticulum; OS, oxidative stress; ROS, reactive oxygen species.</span></p>
<p style="top:36.9pt;left:37.6pt;line-height:6.4pt"><span style="font-family:AdvOT7fb33346.I,serif;font-size:6.4pt">E. Ramos, et al.</span></p>
<p style="top:36.8pt;left:397.5pt;line-height:6.4pt"><i><span style="font-family:CharisSIL,serif;font-size:6.4pt">Toxicology and Applied Pharm</span></i></p>
<p style="top:36.8pt;left:480.1pt;line-height:6.4pt"><i><span style="font-family:CharisSIL,serif;font-size:6.4pt">acology 392 (2020) 114933</span></i></p>
<p style="top:760.9pt;left:295.8pt;line-height:6.4pt"><span style="font-family:CharisSIL,serif;font-size:6.4pt">5</span></p>


<p style="top:196.7pt;left:37.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5">2001</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5"> Aly et al., 2015</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5"> Ahmad et al., 2018</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">) and three used adults</span></p>
<p style="top:207.1pt;left:37.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">(</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5">Dianatkhah et al., 2017</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5"> Grima et al., 2018</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5"> Zhao et al., 2018</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">). The</span></p>
<p style="top:217.6pt;left:37.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">involved 278 stroke/hypoxic patients, from which 113 where adults</span></p>
<p style="top:228.0pt;left:37.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">and 145 newborns. These studies showed that melatonin treatment</span></p>
<p style="top:238.5pt;left:37.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">compared with placebo or non-treated patients (</span><span style="font-family:AdvOT7fb33346.I,serif;font-size:8.0pt">i</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">) reduced oxidation</span></p>
<p style="top:249.0pt;left:37.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">and in</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:8.0pt">&#xfb02;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">ammation processes after stroke or asphyxia, (</span><span style="font-family:AdvOT7fb33346.I,serif;font-size:8.0pt">ii</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">) improved</span></p>
<p style="top:259.5pt;left:37.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">survival rate in newborns and intubated stroke patients, (</span><span style="font-family:AdvOT7fb33346.I,serif;font-size:8.0pt">iii</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">) regulated</span></p>
<p style="top:269.9pt;left:37.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">sleep and (</span><span style="font-family:AdvOT7fb33346.I,serif;font-size:8.0pt">iv</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">) improved neurodevelopmental outcomes in asphyxiated</span></p>
<p style="top:280.4pt;left:37.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">newborns. After melatonin treatment in adults, there were no bene</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">ts</span></p>
<p style="top:290.8pt;left:37.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">reported regarding life quality. Such information would have been of</span></p>
<p style="top:301.3pt;left:37.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">great importance, given the dire consequences of stroke. Nevertheless,</span></p>
<p style="top:311.8pt;left:37.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">in one of the newborn studies, favorable neurodevelopmental outcomes</span></p>
<p style="top:322.2pt;left:37.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">were observed after treatment; these outcomes were evaluated at six</span></p>
<p style="top:332.7pt;left:37.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">months of age (</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5">Aly et al., 2015</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">). Interestingly, no serious adverse e</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:8.0pt">&#xfb00;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">ects</span></p>
<p style="top:343.1pt;left:37.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">were reported in any of these studies as consequence of melatonin</span></p>
<p style="top:353.6pt;left:37.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">treatment. Relative to information on the melatonin safety in literature,</span></p>
<p style="top:364.1pt;left:37.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">no melatonin safety conclusions can be drawn from the results on the</span></p>
<p style="top:374.5pt;left:37.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">RCTs (</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5">Seabra et al., 2000</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5"> Andersen et al., 2016</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5"> Foley and Steel, 2019</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">).</span></p>
<p style="top:385.0pt;left:50.1pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">There are some limitations to this review. These limitations in-</span></p>
<p style="top:395.5pt;left:37.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">cluded the small number of RCTs, uncertainty regarding blinding of</span></p>
<p style="top:405.9pt;left:37.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">participants</span></p>
<p style="top:405.9pt;left:86.9pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">and</span></p>
<p style="top:405.9pt;left:107.3pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">personnel,</span></p>
<p style="top:405.9pt;left:151.3pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">and</span></p>
<p style="top:405.9pt;left:171.8pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">a</span></p>
<p style="top:405.9pt;left:183.3pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">small</span></p>
<p style="top:405.9pt;left:209.4pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">number</span></p>
<p style="top:405.9pt;left:244.1pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">of</span></p>
<p style="top:405.9pt;left:258.5pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">patients.</span></p>
<p style="top:416.4pt;left:37.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">Additionally, the heterogeneity of measured outcomes limited general</span></p>
<p style="top:426.8pt;left:37.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">conclusions and made impossible direct comparisons or meta-analyses</span></p>
<p style="top:437.3pt;left:37.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">about the e</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:8.0pt">&#xfb03;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">cacy of melatonin in stroke.</span></p>
<p style="top:447.7pt;left:50.1pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">As described in this systematic review, there are numerous reports</span></p>
<p style="top:458.2pt;left:37.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">in the scienti</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">c literature that document melatonin as an e</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:8.0pt">&#xfb00;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">ective</span></p>
<p style="top:468.7pt;left:37.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">molecule in di</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:8.0pt">&#xfb00;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">erent</span><span style="font-family:AdvOT7fb33346.I,serif;font-size:8.0pt"> in vitro</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt"> and</span><span style="font-family:AdvOT7fb33346.I,serif;font-size:8.0pt"> in vivo</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt"> stroke models. The mechanisms</span></p>
<p style="top:479.1pt;left:37.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">by which melatonin exerts these protective e</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:8.0pt">&#xfb00;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">ects are widely described</span></p>
<p style="top:489.6pt;left:37.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">in the literature; but, translational data for clinical studies are lacking.</span></p>
<p style="top:500.1pt;left:37.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">While this review reveals a lack of clinical studies the results that were</span></p>
<p style="top:510.5pt;left:37.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">reported were promising in the few RCTs carried out to date. No clinical</span></p>
<p style="top:521.0pt;left:37.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">trials of melatonin pretreatment have been reported, while in animals,</span></p>
<p style="top:531.4pt;left:37.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">highly protective results have been obtained when melatonin was used</span></p>
<p style="top:541.9pt;left:37.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">as a preventive therapy for ischemic brain injury (</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5">Pei and Cheung,</span></p>
<p style="top:552.3pt;left:37.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5">2004</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5"> Liu and Cheung, 2013</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5"> Li et al., 2014</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5"> Tang et al., 2014</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">).</span></p>
<p style="top:562.8pt;left:50.1pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">The pleiotropy of melatonin as a neuromodulator of in</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:8.0pt">&#xfb02;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">ammatory</span></p>
<p style="top:573.2pt;left:37.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">response, its ability to counteract free radical-mediated injury, regulate</span></p>
<p style="top:583.7pt;left:37.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">antioxidant activity and suppress excitotoxicity has been well-estab-</span></p>
<p style="top:594.2pt;left:37.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">lished (</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5">Manchester et al., 2015</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt;color:#2a7ca5"> Tan and Reiter, 2019</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">). Considering the</span></p>
<p style="top:604.7pt;left:37.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">observations regarding tissue damage reduction, increased cell pro-</span></p>
<p style="top:615.1pt;left:37.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">liferation, and neurogenesis promotion, integrity and permeability of</span></p>
<p style="top:625.6pt;left:37.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">BBB maintenance, as well as its capacity of electrophysiological re-</span></p>
<p style="top:636.0pt;left:37.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">covery improvement either alone or in combination with other ther-</span></p>
<p style="top:646.5pt;left:37.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">apeutic approaches, makes melatonin a suitable molecule, but un-</span></p>
<p style="top:657.0pt;left:37.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">fortunately, not economically pro</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">table option in stroke treatment. The</span></p>
<p style="top:667.4pt;left:37.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">small number of clinical trials with melatonin is likely due to its non-</span></p>
<p style="top:677.9pt;left:37.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">patentable nature (it is a natural product). Melatonin is inexpensive</span></p>
<p style="top:688.3pt;left:37.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">with a limited commercial margin. So, it has not attracted the interest</span></p>
<p style="top:698.8pt;left:37.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">of the pharmaceutical industry.</span></p>
<p style="top:196.7pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT1efcda3b.B,serif;font-size:8.0pt">5. Conclusions</span></p>
<p style="top:217.6pt;left:319.1pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">We found only six articles that include a RCT study of melatonin in</span></p>
<p style="top:228.0pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">stroke or asphyxiated patients; all of these provided evidence that</span></p>
<p style="top:238.5pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">melatonin</span></p>
<p style="top:238.5pt;left:348.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">treatment</span></p>
<p style="top:238.5pt;left:389.4pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">is</span></p>
<p style="top:238.5pt;left:401.4pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">a</span></p>
<p style="top:238.5pt;left:411.9pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">safe</span></p>
<p style="top:238.5pt;left:432.1pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">therapy</span></p>
<p style="top:238.5pt;left:465.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">with</span></p>
<p style="top:238.5pt;left:487.9pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">positive</span></p>
<p style="top:238.5pt;left:522.0pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">outcomes.</span></p>
<p style="top:249.0pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">Nevertheless, there is not su</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:8.0pt">&#xfb03;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">cient available evidence to conclude that</span></p>
<p style="top:259.5pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">the clinical use of melatonin in these patients may be e</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:8.0pt">&#xfb00;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">ective. Clearly,</span></p>
<p style="top:269.9pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">administered doses in subsequent RCTs should be reconsidered, in-</span></p>
<p style="top:280.4pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">asmuch as the extrapolation of animal e</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:8.0pt">&#xfb00;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">ective doses to humans as</span></p>
<p style="top:290.8pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">shown herein suggest the human doses used are likely far too low to</span></p>
<p style="top:301.3pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">signi</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">cantly in</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:8.0pt">&#xfb02;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">uence stroke outcomes in RCTs.</span></p>
<p style="top:322.2pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT1efcda3b.B,serif;font-size:8.0pt">Financial support</span></p>
<p style="top:343.1pt;left:319.1pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">This work was supported by UCJC (JEMELAR); and Fondo de</span></p>
<p style="top:353.6pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">Investigaciones</span></p>
<p style="top:353.6pt;left:367.9pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">Sanitarias</span></p>
<p style="top:353.6pt;left:410.1pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">(FIS)(ISCIII/FEDER)</span></p>
<p style="top:353.6pt;left:488.5pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">(Programa</span></p>
<p style="top:353.6pt;left:533.2pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">Miguel</span></p>
<p style="top:364.1pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">Servet CP14/00008; PI16/00735).</span></p>
<p style="top:385.0pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT1efcda3b.B,serif;font-size:8.0pt">Declaration of Competing Interest</span></p>
<p style="top:405.9pt;left:319.1pt;line-height:8.0pt"><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">The authors declare no con</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:8.0pt">&#xfb02;</span><span style="font-family:AdvOT596495f2,serif;font-size:8.0pt">ict of interest.</span></p>
<p style="top:426.8pt;left:306.6pt;line-height:8.0pt"><span style="font-family:AdvOT1efcda3b.B,serif;font-size:8.0pt">References</span></p>
<p style="top:449.0pt;left:306.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Ahmad, Q.M., Chishti, A.L., Waseem, N., 2018. Role of melatonin in management of</span></p>
<p style="top:457.0pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">hypoxic ischaemic encephalopathy in newborns: a randomized control trial. J. Pak.</span></p>
<p style="top:464.9pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Med. Assoc. 68, 1233</span><span style="font-family:AdvOT596495f2+20,serif;font-size:6.4pt;color:#2a7ca5">&#x2013;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">1237</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">.</span></p>
<p style="top:472.9pt;left:306.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Alluri, H., Wilson, R.L., Anasooya Shaji, C., Wiggins-Dohlvik, K., Patel, S., Liu, Y., Peng,</span></p>
<p style="top:480.9pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">X., Beeram, M.R., Davis, M.L., Huang, J.H., Tharakan, B., 2016. Melatonin preserves</span></p>
<p style="top:488.9pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">blood-brain barrier integrity and permeability via matrix metalloproteinase-9 in-</span></p>
<p style="top:496.9pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">hibition. PLoS One 11, e0154427</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">.</span></p>
<p style="top:504.8pt;left:306.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Alonso-Alconada, D., Alvarez, A., Lacalle, J., Hilario, E., 2012. Histological study of the</span></p>
<p style="top:512.8pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">protective e</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:6.4pt;color:#2a7ca5">&#xfb00;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">ect of melatonin on neural cells after neonatal hypoxia-ischemia. Histol.</span></p>
<p style="top:520.7pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Histopathol. 27, 771</span><span style="font-family:AdvOT596495f2+20,serif;font-size:6.4pt;color:#2a7ca5">&#x2013;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">783</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">.</span></p>
<p style="top:528.7pt;left:306.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Aly, H., Elmahdy, H., El-Dib, M., Rowisha, M., Awny, M., El-Gohary, T., Elbatch, M.,</span></p>
<p style="top:536.7pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Hamisa, M., El-Mashad, A.R., 2015. Melatonin use for neuroprotection in perinatal</span></p>
<p style="top:544.6pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">asphyxia: a randomized controlled pilot study. J. Perinatol. 35, 186</span><span style="font-family:AdvOT596495f2+20,serif;font-size:6.4pt;color:#2a7ca5">&#x2013;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">191</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">.</span></p>
<p style="top:552.6pt;left:306.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Andersen, L.P., Gogenur, I., Rosenberg, J., Reiter, R.J., 2016. The safety of melatonin in</span></p>
<p style="top:560.6pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">humans. Clin. Drug Investig. 36, 169</span><span style="font-family:AdvOT596495f2+20,serif;font-size:6.4pt;color:#2a7ca5">&#x2013;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">175</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">.</span></p>
<p style="top:568.6pt;left:306.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Arendt, J., 2006. Melatonin and human rhythms. Chronobiol. Int. 23, 21</span><span style="font-family:AdvOT596495f2+20,serif;font-size:6.4pt;color:#2a7ca5">&#x2013;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">37</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">.</span></p>
<p style="top:576.6pt;left:306.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Balduini, W., Carloni, S., Perrone, S., Bertrando, S., Tataranno, M.L., Negro, S., Proietti,</span></p>
<p style="top:584.5pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">F., Longini, M., Buonocore, G., 2012. The use of melatonin in hypoxic-ischemic brain</span></p>
<p style="top:592.5pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">damage: an experimental study. J. Matern. Fetal Neonatal Med. 25 (Suppl. 1),</span></p>
<p style="top:600.4pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">119</span><span style="font-family:AdvOT596495f2+20,serif;font-size:6.4pt;color:#2a7ca5">&#x2013;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">124</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">.</span></p>
<p style="top:608.4pt;left:306.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Carloni, S., Perrone, S., Buonocore, G., Longini, M., Proietti, F., Balduini, W., 2008.</span></p>
<p style="top:616.4pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Melatonin protects from the long-term consequences of a neonatal hypoxic-ischemic</span></p>
<p style="top:624.4pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">brain injury in rats. J. Pineal Res. 44, 157</span><span style="font-family:AdvOT596495f2+20,serif;font-size:6.4pt;color:#2a7ca5">&#x2013;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">164</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">.</span></p>
<p style="top:632.4pt;left:306.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Carloni, S., Albertini, M.C., Galluzzi, L., Buonocore, G., Proietti, F., Balduini, W., 2014.</span></p>
<p style="top:640.3pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Melatonin reduces endoplasmic reticulum stress and preserves sirtuin 1 expression in</span></p>
<p style="top:648.3pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">neuronal cells of newborn rats after hypoxia-ischemia. J. Pineal Res. 57, 192</span><span style="font-family:AdvOT596495f2+20,serif;font-size:6.4pt;color:#2a7ca5">&#x2013;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">199</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">.</span></p>
<p style="top:656.2pt;left:306.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Chan, P.H., 2001. Reactive oxygen radicals in signaling and damage in the ischemic brain.</span></p>
<p style="top:664.2pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">J. Cereb. Blood Flow Metab. 21, 2</span><span style="font-family:AdvOT596495f2+20,serif;font-size:6.4pt;color:#2a7ca5">&#x2013;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">14</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">.</span></p>
<p style="top:672.2pt;left:306.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Chen, H.Y., Chen, T.Y., Lee, M.Y., Chen, S.T., Hsu, Y.S., Kuo, Y.L., Chang, G.L., Wu, T.S.,</span></p>
<p style="top:680.1pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Lee, E.J., 2006. Melatonin decreases neurovascular oxidative/nitrosative damage and</span></p>
<p style="top:688.1pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">protects against early increases in the blood-brain barrier permeability after transient</span></p>
<p style="top:696.1pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">focal cerebral ischemia in mice. J. Pineal Res. 41, 175</span><span style="font-family:AdvOT596495f2+20,serif;font-size:6.4pt;color:#2a7ca5">&#x2013;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">182</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">.</span></p>
<p style="top:704.1pt;left:306.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Chen, H.Y., Hung, Y.C., Chen, T.Y., Huang, S.Y., Wang, Y.H., Lee, W.T., Wu, T.S., Lee,</span></p>
<p style="top:712.1pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">E.J., 2009. Melatonin improves presynaptic protein, SNAP-25, expression and den-</span></p>
<p style="top:720.0pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">dritic spine density and enhances functional and electrophysiological recovery fol-</span></p>
<p style="top:728.0pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">lowing transient focal cerebral ischemia in rats. J. Pineal Res. 47, 260</span><span style="font-family:AdvOT596495f2+20,serif;font-size:6.4pt;color:#2a7ca5">&#x2013;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">270</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">.</span></p>
<p style="top:735.9pt;left:306.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Dehghan, F., Khaksari Hadad, M., Asadikram, G., Naja</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:6.4pt;color:#2a7ca5">&#xfb01;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">pour, H., Shahrokhi, N., 2013.</span></p>
<p style="top:59.4pt;left:37.6pt;line-height:7.2pt"><span style="font-family:AdvOT1efcda3b.B,serif;font-size:7.2pt">Table 5</span></p>
<p style="top:68.9pt;left:37.6pt;line-height:7.2pt"><span style="font-family:AdvOT596495f2,serif;font-size:7.2pt">Common melatonin treatment outcomes reported in the 6 RCTs and in the animal model studies.</span></p>
<p style="top:83.9pt;left:43.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Outcomes</span></p>
<p style="top:83.9pt;left:174.5pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Human</span></p>
<p style="top:83.9pt;left:290.8pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Animal</span></p>
<p style="top:100.3pt;left:43.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Oxidative stress regulation</span></p>
<p style="top:100.3pt;left:174.5pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">(</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Fulia et al., 2001</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">) (</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Aly et al., 2015</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">)</span></p>
<p style="top:108.9pt;left:174.5pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">(</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Zhao et al., 2018</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">)</span></p>
<p style="top:100.3pt;left:290.8pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">(</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Chen et al., 2006</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">) (</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Yang et al., 2015</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">) (</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Giusti et al., 1996a</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">,</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5"> Giusti et al., 1996b</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">,</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5"> Uz et al.,</span></p>
<p style="top:108.9pt;left:290.8pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">1996</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">,</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5"> Floreani et al., 1997</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">) (</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Ozacmak et al., 2009</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">) (</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Sinha et al., 2001</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">) (</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Tutunculer et al.,</span></p>
<p style="top:117.5pt;left:290.8pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">2005</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">) (</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Balduini et al., 2012</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">) (</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Revuelta et al., 2016</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">) (</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Signorini et al., 2009</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">)</span></p>
<p style="top:126.0pt;left:43.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">In</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:6.4pt">&#xfb02;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">ammation regulation</span></p>
<p style="top:126.0pt;left:174.5pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">(</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Zhao et al., 2018</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">)</span></p>
<p style="top:126.0pt;left:290.8pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">(</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Pei and Cheung, 2004</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">) (</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Lee et al., 2007</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">) (</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Paredes et al., 2015</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">) (</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Balduini et al., 2012</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">)</span></p>
<p style="top:134.6pt;left:290.8pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">(</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Villapol et al., 2011</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">) (</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Welin et al., 2007</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">)</span></p>
<p style="top:143.2pt;left:43.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Survival rate improvement</span></p>
<p style="top:143.2pt;left:174.5pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Dianatkhah et al., 2017</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">) (</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Ahmad</span></p>
<p style="top:151.7pt;left:174.5pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">et al., 2018</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">)</span></p>
<p style="top:143.2pt;left:290.8pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">(</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Kilic et al., 2008</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">) (</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Giusti et al., 1996a</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">,</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5"> Giusti et al., 1996b</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">,</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5"> Uz et al., 1996</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">,</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5"> Floreani et al.,</span></p>
<p style="top:151.7pt;left:290.8pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">1997</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">)</span></p>
<p style="top:160.3pt;left:43.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">Neurodevelopmental outcomes</span></p>
<p style="top:168.9pt;left:55.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">improvement</span></p>
<p style="top:160.3pt;left:174.5pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">(</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Aly et al., 2015</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">)</span></p>
<p style="top:160.3pt;left:290.8pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">(</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Kilic et al., 2008</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">) (</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Lee et al., 2004</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">) (</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Giusti et al., 1996a</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">,</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5"> Giusti et al., 1996b</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">,</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5"> Uz et al., 1996</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">,</span></p>
<p style="top:168.9pt;left:290.8pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Floreani et al., 1997</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">) (</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Deykun et al., 2011</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">) (</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Sinha et al., 2001</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">) (</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Carloni et al., 2008</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">)</span></p>
<p style="top:36.9pt;left:37.6pt;line-height:6.4pt"><span style="font-family:AdvOT7fb33346.I,serif;font-size:6.4pt">E. Ramos, et al.</span></p>
<p style="top:36.8pt;left:397.5pt;line-height:6.4pt"><i><span style="font-family:CharisSIL,serif;font-size:6.4pt">Toxicology and Applied Pharm</span></i></p>
<p style="top:36.8pt;left:480.1pt;line-height:6.4pt"><i><span style="font-family:CharisSIL,serif;font-size:6.4pt">acology 392 (2020) 114933</span></i></p>
<p style="top:760.9pt;left:295.8pt;line-height:6.4pt"><span style="font-family:CharisSIL,serif;font-size:6.4pt">6</span></p>


<p style="top:60.0pt;left:49.5pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">E</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:6.4pt;color:#2a7ca5">&#xfb00;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">ect of melatonin on intracranial pressure and brain edema following traumatic</span></p>
<p style="top:68.0pt;left:49.5pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">brain injury: role of oxidative stresses. Arch. Med. Res. 44, 251</span><span style="font-family:AdvOT596495f2+20,serif;font-size:6.4pt;color:#2a7ca5">&#x2013;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">258</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">.</span></p>
<p style="top:76.0pt;left:37.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Deykun, K., Pometlova, M., Schutova, B., Mares, J., 2011. Modulations of behavioral</span></p>
<p style="top:83.9pt;left:49.5pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">consequences of minor cortical ischemic lesion by application of free radicals sca-</span></p>
<p style="top:91.9pt;left:49.5pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">vengers. Gen. Physiol. Biophys. 30, 263</span><span style="font-family:AdvOT596495f2+20,serif;font-size:6.4pt;color:#2a7ca5">&#x2013;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">270</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">.</span></p>
<p style="top:99.8pt;left:37.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Dianatkhah, M., Naja</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:6.4pt;color:#2a7ca5">&#xfb01;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">, A., Sharifzadeh, M., Ahmadi, A., Sharifnia, H., Mojtahedzadeh,</span></p>
<p style="top:107.8pt;left:49.5pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">M., Najmeddin, F., Moghaddas, A., 2017. Melatonin supplementation may improve</span></p>
<p style="top:115.8pt;left:49.5pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">the outcome of patients with Hemorrhagic stroke in the intensive care unit. J. Res.</span></p>
<p style="top:123.8pt;left:49.5pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Pharm. Pract. 6, 173</span><span style="font-family:AdvOT596495f2+20,serif;font-size:6.4pt;color:#2a7ca5">&#x2013;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">177</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">.</span></p>
<p style="top:131.8pt;left:37.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Feigin, V.L., Forouzanfar, M.H., Krishnamurthi, R., Mensah, G.A., Connor, M., Bennett,</span></p>
<p style="top:139.7pt;left:49.5pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">D.A., Moran, A.E., Sacco, R.L., Anderson, L., Truelsen, T., O</span><span style="font-family:AdvOT596495f2+20,serif;font-size:6.4pt;color:#2a7ca5">&#x2019;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Donnell, M.,</span></p>
<p style="top:147.7pt;left:49.5pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Venketasubramanian, N., Barker-Collo, S., Lawes, C.M., Wang, W., Shinohara, Y.,</span></p>
<p style="top:155.7pt;left:49.5pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Witt, E., Ezzati, M., Naghavi, M., Murray, C., Global Burden of Diseases, I., Risk</span></p>
<p style="top:163.6pt;left:49.5pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Factors, S., the, G.B.D.S.E.G, 2014. Global and regional burden of stroke during 1990-</span></p>
<p style="top:171.6pt;left:49.5pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">2010:</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:6.4pt;color:#2a7ca5"> &#xfb01;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">ndings from the global burden of disease study 2010. Lancet. 383, 245</span><span style="font-family:AdvOT596495f2+20,serif;font-size:6.4pt;color:#2a7ca5">&#x2013;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">254</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">.</span></p>
<p style="top:179.5pt;left:37.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Fiorina, P., Lattuada, G., Ponari, O., Silvestrini, C., DallAglio, P., 1996. Impaired noc-</span></p>
<p style="top:187.5pt;left:49.5pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">turnal melatonin excretion and changes of immunological status in ischaemic stroke</span></p>
<p style="top:195.5pt;left:49.5pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">patients. Lancet 347, 692</span><span style="font-family:AdvOT596495f2+20,serif;font-size:6.4pt;color:#2a7ca5">&#x2013;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">693</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">.</span></p>
<p style="top:203.5pt;left:37.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Floreani, M., Skaper, S.D., Facci, L., Lipartiti, M., Giusti, P., 1997. Melatonin maintains</span></p>
<p style="top:211.5pt;left:49.5pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">glutathione homeostasis in kainic acid-exposed rat brain tissues. FASEB J. 11,</span></p>
<p style="top:219.4pt;left:49.5pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">1309</span><span style="font-family:AdvOT596495f2+20,serif;font-size:6.4pt;color:#2a7ca5">&#x2013;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">1315</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">.</span></p>
<p style="top:227.4pt;left:37.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Foley, H.M., Steel, A.E., 2019. Adverse events associated with oral administration of</span></p>
<p style="top:235.3pt;left:49.5pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">melatonin: a critical systematic review of clinical evidence. Complement. Ther. Med.</span></p>
<p style="top:243.3pt;left:49.5pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">42, 65</span><span style="font-family:AdvOT596495f2+20,serif;font-size:6.4pt;color:#2a7ca5">&#x2013;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">81</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">.</span></p>
<p style="top:251.3pt;left:37.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Fulia, F., Gitto, E., Cuzzocrea, S., Reiter, R.J., Dugo, L., Gitto, P., Barberi, S., Cordaro, S.,</span></p>
<p style="top:259.3pt;left:49.5pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Barberi, I., 2001. Increased levels of malondialdehyde and nitrite/nitrate in the blood</span></p>
<p style="top:267.2pt;left:49.5pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">of asphyxiated newborns: reduction by melatonin. J. Pineal Res. 31, 343</span><span style="font-family:AdvOT596495f2+20,serif;font-size:6.4pt;color:#2a7ca5">&#x2013;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">349</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">.</span></p>
<p style="top:275.2pt;left:37.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Giusti, P., Franceschini, D., Petrone, M., Manev, H., Floreani, M., 1996a. In vitro and in</span></p>
<p style="top:283.2pt;left:49.5pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">vivo protection against kainate-induced excitotoxicity by melatonin. J. Pineal Res.</span></p>
<p style="top:291.1pt;left:49.5pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">20, 226</span><span style="font-family:AdvOT596495f2+20,serif;font-size:6.4pt;color:#2a7ca5">&#x2013;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">231</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">.</span></p>
<p style="top:299.1pt;left:37.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Giusti, P., Lipartiti, M., Franceschini, D., Schiavo, N., Floreani, M., Manev, H., 1996b.</span></p>
<p style="top:307.1pt;left:49.5pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Neuroprotection by melatonin from kainate-induced excitotoxicity in rats. FASEB J.</span></p>
<p style="top:315.0pt;left:49.5pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">10, 891</span><span style="font-family:AdvOT596495f2+20,serif;font-size:6.4pt;color:#2a7ca5">&#x2013;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">896</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">.</span></p>
<p style="top:323.0pt;left:37.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Grima, N.A., Rajaratnam, S.M.W., Mans</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:6.4pt;color:#2a7ca5">&#xfb01;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">eld, D., Sletten, T.L., Spitz, G., Ponsford, J.L.,</span></p>
<p style="top:331.0pt;left:49.5pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">2018. E</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:6.4pt;color:#2a7ca5">&#xfb03;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">cacy of melatonin for sleep disturbance following traumatic brain injury: a</span></p>
<p style="top:339.0pt;left:49.5pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">randomised controlled trial. BMC Med. 16, 8</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">.</span></p>
<p style="top:347.0pt;left:37.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Guzik, A., Bushnell, C., 2017. Stroke epidemiology and risk factor management.</span></p>
<p style="top:354.9pt;left:49.5pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Continuum. (Minneap Minn) 23, 15</span><span style="font-family:AdvOT596495f2+20,serif;font-size:6.4pt;color:#2a7ca5">&#x2013;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">39</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">.</span></p>
<p style="top:362.9pt;left:37.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Higgins, J.P., Altman, D.G., Gotzsche, P.C., Juni, P., Moher, D., Oxman, A.D., Savovic, J.,</span></p>
<p style="top:370.8pt;left:49.5pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Schulz, K.F., Weeks, L., Sterne, J.A., Cochrane Bias Methods, G., Cochrane Statistical</span></p>
<p style="top:378.8pt;left:49.5pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Methods, G., 2011. The Cochrane collaboration&apos;s tool for assessing risk of bias in</span></p>
<p style="top:386.8pt;left:49.5pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">randomised trials. BMJ. 343, d5928</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">.</span></p>
<p style="top:394.7pt;left:37.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Hung, Y.C., Chen, T.Y., Lee, E.J., Chen, W.L., Huang, S.Y., Lee, W.T., Lee, M.Y., Chen,</span></p>
<p style="top:402.7pt;left:49.5pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">H.Y., Wu, T.S., 2008. Melatonin decreases matrix metalloproteinase-9 activation and</span></p>
<p style="top:410.7pt;left:49.5pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">expression and attenuates reperfusion-induced hemorrhage following transient focal</span></p>
<p style="top:418.7pt;left:49.5pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">cerebral ischemia in rats. J. Pineal Res. 45, 459</span><span style="font-family:AdvOT596495f2+20,serif;font-size:6.4pt;color:#2a7ca5">&#x2013;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">467</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">.</span></p>
<p style="top:426.6pt;left:37.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Iadecola, C., Alexander, M., 2001. Cerebral ischemia and in</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:6.4pt;color:#2a7ca5">&#xfb02;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">ammation. Curr. Opin.</span></p>
<p style="top:434.6pt;left:49.5pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Neurol. 14, 89</span><span style="font-family:AdvOT596495f2+20,serif;font-size:6.4pt;color:#2a7ca5">&#x2013;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">94</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">.</span></p>
<p style="top:442.6pt;left:37.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Jang, J.W., Lee, J.K., Lee, M.C., Piao, M.S., Kim, S.H., Kim, H.S., 2012. Melatonin reduced</span></p>
<p style="top:450.5pt;left:49.5pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">the elevated matrix metalloproteinase-9 level in a rat photothrombotic stroke model.</span></p>
<p style="top:458.5pt;left:49.5pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">J. Neurol. Sci. 323, 221</span><span style="font-family:AdvOT596495f2+20,serif;font-size:6.4pt;color:#2a7ca5">&#x2013;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">227</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">.</span></p>
<p style="top:466.5pt;left:37.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Juan, W.S., Huang, S.Y., Chang, C.C., Hung, Y.C., Lin, Y.W., Chen, T.Y., Lee, A.H., Lee,</span></p>
<p style="top:474.5pt;left:49.5pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">A.C., Wu, T.S., Lee, E.J., 2014. Melatonin improves neuroplasticity by upregulating</span></p>
<p style="top:482.5pt;left:49.5pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">the growth-associated protein-43 (GAP-43) and NMDAR postsynaptic density-95</span></p>
<p style="top:490.4pt;left:49.5pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">(PSD-95) proteins in cultured neurons exposed to glutamate excitotoxicity and in rats</span></p>
<p style="top:498.4pt;left:49.5pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">subjected to transient focal cerebral ischemia even during a long-term recovery</span></p>
<p style="top:506.3pt;left:49.5pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">period. J. Pineal Res. 56, 213</span><span style="font-family:AdvOT596495f2+20,serif;font-size:6.4pt;color:#2a7ca5">&#x2013;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">223</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">.</span></p>
<p style="top:514.3pt;left:37.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Kilic, E., Kilic, U., Reiter, R.J., Bassetti, C.L., Hermann, D.M., 2004a. Prophylactic use of</span></p>
<p style="top:522.3pt;left:49.5pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">melatonin protects against focal cerebral ischemia in mice: role of endothelin con-</span></p>
<p style="top:530.2pt;left:49.5pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">verting enzyme-1. J. Pineal Res. 37, 247</span><span style="font-family:AdvOT596495f2+20,serif;font-size:6.4pt;color:#2a7ca5">&#x2013;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">251</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">.</span></p>
<p style="top:538.2pt;left:37.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Kilic, E., Kilic, U., Yulug, B., Hermann, D.M., Reiter, R.J., 2004b. Melatonin reduces</span></p>
<p style="top:546.2pt;left:49.5pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">disseminate neuronal death after mild focal ischemia in mice via inhibition of cas-</span></p>
<p style="top:554.2pt;left:49.5pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">pase-3 and is suitable as an add-on treatment to tissue-plasminogen activator. J.</span></p>
<p style="top:562.1pt;left:49.5pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Pineal Res. 36, 171</span><span style="font-family:AdvOT596495f2+20,serif;font-size:6.4pt;color:#2a7ca5">&#x2013;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">176</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">.</span></p>
<p style="top:570.1pt;left:37.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Kilic, E., Kilic, U., Reiter, R.J., Bassetti, C.L., Hermann, D.M., 2005a. Tissue-plasminogen</span></p>
<p style="top:578.1pt;left:49.5pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">activator-induced ischemic brain injury is reversed by melatonin: role of iNOS and</span></p>
<p style="top:586.0pt;left:49.5pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Akt. J. Pineal Res. 39, 151</span><span style="font-family:AdvOT596495f2+20,serif;font-size:6.4pt;color:#2a7ca5">&#x2013;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">155</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">.</span></p>
<p style="top:594.0pt;left:37.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Kilic, U., Kilic, E., Reiter, R.J., Bassetti, C.L., Hermann, D.M., 2005b. Signal transduction</span></p>
<p style="top:602.0pt;left:49.5pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">pathways involved in melatonin-induced neuroprotection after focal cerebral</span></p>
<p style="top:610.0pt;left:49.5pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">ischemia in mice. J. Pineal Res. 38, 67</span><span style="font-family:AdvOT596495f2+20,serif;font-size:6.4pt;color:#2a7ca5">&#x2013;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">71</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">.</span></p>
<p style="top:617.9pt;left:37.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Kilic, E., Kilic, U., Bacigaluppi, M., Guo, Z., Abdallah, N.B., Wolfer, D.P., Reiter, R.J.,</span></p>
<p style="top:625.9pt;left:49.5pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Hermann, D.M., Bassetti, C.L., 2008. Delayed melatonin administration promotes</span></p>
<p style="top:633.9pt;left:49.5pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">neuronal survival, neurogenesis and motor recovery, and attenuates hyperactivity</span></p>
<p style="top:641.8pt;left:49.5pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">and anxiety after mild focal cerebral ischemia in mice. J. Pineal Res. 45, 142</span><span style="font-family:AdvOT596495f2+20,serif;font-size:6.4pt;color:#2a7ca5">&#x2013;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">148</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">.</span></p>
<p style="top:649.8pt;left:37.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Kim, S.J., Lee, S.R., 2014. Protective e</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:6.4pt;color:#2a7ca5">&#xfb00;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">ect of melatonin against transient global cerebral</span></p>
<p style="top:657.7pt;left:49.5pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">ischemia-induced neuronal cell damage via inhibition of matrix metalloproteinase-9.</span></p>
<p style="top:665.7pt;left:49.5pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Life Sci. 94, 8</span><span style="font-family:AdvOT596495f2+20,serif;font-size:6.4pt;color:#2a7ca5">&#x2013;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">16</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">.</span></p>
<p style="top:673.7pt;left:37.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Kitkhuandee, A., Sawanyawisuth, K., Johns, J., Kanpittaya, J., Tuntapakul, S., Johns,</span></p>
<p style="top:681.7pt;left:49.5pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">N.P., 2014a. Pineal calci</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:6.4pt;color:#2a7ca5">&#xfb01;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">cation is a novel risk factor for symptomatic intracerebral</span></p>
<p style="top:689.7pt;left:49.5pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">hemorrhage. Clin. Neurol. Neurosurg. 121, 51</span><span style="font-family:AdvOT596495f2+20,serif;font-size:6.4pt;color:#2a7ca5">&#x2013;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">54</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">.</span></p>
<p style="top:697.6pt;left:37.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Kitkhuandee, A., Sawanyawisuth, K., Johns, N.P., Kanpittaya, J., Johns, J., 2014b. Pineal</span></p>
<p style="top:705.6pt;left:49.5pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">calci</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:6.4pt;color:#2a7ca5">&#xfb01;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">cation is associated with symptomatic cerebral infarction. J. Stroke</span></p>
<p style="top:713.5pt;left:49.5pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Cerebrovasc. Dis. 23, 249</span><span style="font-family:AdvOT596495f2+20,serif;font-size:6.4pt;color:#2a7ca5">&#x2013;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">253</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">.</span></p>
<p style="top:721.5pt;left:37.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Koh, P.O., 2008a. Melatonin attenuates the cerebral ischemic injury via the MEK/ERK/</span></p>
<p style="top:729.5pt;left:49.5pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">p90RSK/bad signaling cascade. J. Vet. Med. Sci. 70, 1219</span><span style="font-family:AdvOT596495f2+20,serif;font-size:6.4pt;color:#2a7ca5">&#x2013;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">1223</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">.</span></p>
<p style="top:737.5pt;left:37.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Koh, P.O., 2008b. Melatonin prevents the injury-induced decline of Akt/forkhead</span></p>
<p style="top:60.0pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">transcription factors phosphorylation. J. Pineal Res. 45, 199</span><span style="font-family:AdvOT596495f2+20,serif;font-size:6.4pt;color:#2a7ca5">&#x2013;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">203</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">.</span></p>
<p style="top:68.0pt;left:306.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Koh, P.O., 2008c. Melatonin regulates nitric oxide synthase expression in ischemic brain</span></p>
<p style="top:76.0pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">injury. J. Vet. Med. Sci. 70, 747</span><span style="font-family:AdvOT596495f2+20,serif;font-size:6.4pt;color:#2a7ca5">&#x2013;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">750</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">.</span></p>
<p style="top:83.9pt;left:306.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Koh, P.O., 2012. Melatonin attenuates decrease of protein phosphatase 2A subunit B in</span></p>
<p style="top:91.9pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">ischemic brain injury. J. Pineal Res. 52, 57</span><span style="font-family:AdvOT596495f2+20,serif;font-size:6.4pt;color:#2a7ca5">&#x2013;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">61</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">.</span></p>
<p style="top:99.8pt;left:306.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Kondoh, T., Uneyama, H., Nishino, H., Torii, K., 2002. Melatonin reduces cerebral edema</span></p>
<p style="top:107.8pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">formation caused by transient forebrain ischemia in rats. Life Sci. 72, 583</span><span style="font-family:AdvOT596495f2+20,serif;font-size:6.4pt;color:#2a7ca5">&#x2013;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">590</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">.</span></p>
<p style="top:115.8pt;left:306.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Lee, E.J., Wu, T.S., Lee, M.Y., Chen, T.Y., Tsai, Y.Y., Chuang, J.I., Chang, G.L., 2004.</span></p>
<p style="top:123.8pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Delayed treatment with melatonin enhances electrophysiological recovery following</span></p>
<p style="top:131.7pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">transient focal cerebral ischemia in rats. J. Pineal Res. 36, 33</span><span style="font-family:AdvOT596495f2+20,serif;font-size:6.4pt;color:#2a7ca5">&#x2013;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">42</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">.</span></p>
<p style="top:139.7pt;left:306.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Lee, M.Y., Kuan, Y.H., Chen, H.Y., Chen, T.Y., Chen, S.T., Huang, C.C., Yang, I.P., Hsu,</span></p>
<p style="top:147.7pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Y.S., Wu, T.S., Lee, E.J., 2007. Intravenous administration of melatonin reduces the</span></p>
<p style="top:155.7pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">intracerebral cellular in</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:6.4pt;color:#2a7ca5">&#xfb02;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">ammatory response following transient focal cerebral</span></p>
<p style="top:163.6pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">ischemia in rats. J. Pineal Res. 42, 297</span><span style="font-family:AdvOT596495f2+20,serif;font-size:6.4pt;color:#2a7ca5">&#x2013;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">309</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">.</span></p>
<p style="top:171.6pt;left:306.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Li, H., Wang, Y., Feng, D., Liu, Y., Xu, M., Gao, A., Tian, F., Zhang, L., Cui, Y., Wang, Z.,</span></p>
<p style="top:179.5pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Chen, G., 2014. Alterations in the time course of expression of the Nox family in the</span></p>
<p style="top:187.5pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">brain in a rat experimental cerebral ischemia and reperfusion model: e</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:6.4pt;color:#2a7ca5">&#xfb00;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">ects of</span></p>
<p style="top:195.5pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">melatonin. J. Pineal Res. 57, 110</span><span style="font-family:AdvOT596495f2+20,serif;font-size:6.4pt;color:#2a7ca5">&#x2013;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">119</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">.</span></p>
<p style="top:203.5pt;left:306.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Liu, L., Cheung, R.T., 2013. E</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:6.4pt;color:#2a7ca5">&#xfb00;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">ects of pretreatment with a combination of melatonin and</span></p>
<p style="top:211.5pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">electroacupuncture in a rat model of transient focal cerebral ischemia. Evid. Based</span></p>
<p style="top:219.4pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Complement. Alternat. Med. 2013, 953162</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">.</span></p>
<p style="top:227.4pt;left:306.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Lo, E.H., Moskowitz, M.A., Jacobs, T.P., 2005. Exciting, radical, suicidal: how brain cells</span></p>
<p style="top:235.3pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">die after stroke. Stroke. 36, 189</span><span style="font-family:AdvOT596495f2+20,serif;font-size:6.4pt;color:#2a7ca5">&#x2013;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">192</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">.</span></p>
<p style="top:243.3pt;left:306.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Manchester, L.C., Coto-Montes, A., Boga, J.A., Andersen, L.P., Zhou, Z., Galano, A.,</span></p>
<p style="top:251.3pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Vriend, J., Tan, D.X., Reiter, R.J., 2015. Melatonin: an ancient molecule that makes</span></p>
<p style="top:259.3pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">oxygen metabolically tolerable. J. Pineal Res. 59, 403</span><span style="font-family:AdvOT596495f2+20,serif;font-size:6.4pt;color:#2a7ca5">&#x2013;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">419</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">.</span></p>
<p style="top:267.3pt;left:306.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Melo, M.C.A., Abreu, R.L.C., Linhares Neto, V.B., de Bruin, P.F.C., de Bruin, V.M.S., 2017.</span></p>
<p style="top:275.2pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Chronotype and circadian rhythm in bipolar disorder: a systematic review. Sleep</span></p>
<p style="top:283.2pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Med. Rev. 34, 46</span><span style="font-family:AdvOT596495f2+20,serif;font-size:6.4pt;color:#2a7ca5">&#x2013;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">58</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">.</span></p>
<p style="top:291.1pt;left:306.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group, 1995.</span></p>
<p style="top:299.1pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Tissue plasminogen activator for acute ischemic stroke. N. Engl. J. Med. 333,</span></p>
<p style="top:307.1pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">1581</span><span style="font-family:AdvOT596495f2+20,serif;font-size:6.4pt;color:#2a7ca5">&#x2013;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">1587</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">.</span></p>
<p style="top:315.0pt;left:306.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Niizuma, K., Yoshioka, H., Chen, H., Kim, G.S., Jung, J.E., Katsu, M., Okami, N., Chan,</span></p>
<p style="top:323.0pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">P.H., 2010. Mitochondrial and apoptotic neuronal death signaling pathways in cer-</span></p>
<p style="top:331.0pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">ebral ischemia. Biochim. Biophys. Acta 1802, 92</span><span style="font-family:AdvOT596495f2+20,serif;font-size:6.4pt;color:#2a7ca5">&#x2013;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">99</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">.</span></p>
<p style="top:339.0pt;left:306.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Ozacmak, V.H., Barut, F., Ozacmak, H.S., 2009. Melatonin provides neuroprotection by</span></p>
<p style="top:347.0pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">reducing oxidative stress and HSP70 expression during chronic cerebral hypoperfu-</span></p>
<p style="top:354.9pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">sion in ovariectomized rats. J. Pineal Res. 47, 156</span><span style="font-family:AdvOT596495f2+20,serif;font-size:6.4pt;color:#2a7ca5">&#x2013;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">163</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">.</span></p>
<p style="top:362.9pt;left:306.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Paredes, S.D., Rancan, L., Kireev, R., Gonzalez, A., Louzao, P., Gonzalez, P., Rodriguez-</span></p>
<p style="top:370.8pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Bobada, C., Garcia, C., Vara, E., Tresguerres, J.A., 2015. Melatonin counteracts at a</span></p>
<p style="top:378.8pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">transcriptional level the in</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:6.4pt;color:#2a7ca5">&#xfb02;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">ammatory and apoptotic response secondary to ischemic</span></p>
<p style="top:386.8pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">brain injury induced by middle cerebral artery blockade in aging rats. Biores. Open</span></p>
<p style="top:394.8pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Access. 4, 407</span><span style="font-family:AdvOT596495f2+20,serif;font-size:6.4pt;color:#2a7ca5">&#x2013;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">416</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">.</span></p>
<p style="top:402.7pt;left:306.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Paschen, W., 2000. Role of calcium in neuronal cell injury: which subcellular compart-</span></p>
<p style="top:410.7pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">ment is involved? Brain Res. Bull. 53, 409</span><span style="font-family:AdvOT596495f2+20,serif;font-size:6.4pt;color:#2a7ca5">&#x2013;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">413</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">.</span></p>
<p style="top:418.7pt;left:306.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Pei, Z., Cheung, R.T., 2004. Pretreatment with melatonin exerts anti-in</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:6.4pt;color:#2a7ca5">&#xfb02;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">ammatory e</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:6.4pt;color:#2a7ca5">&#xfb00;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">ects</span></p>
<p style="top:426.6pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">against ischemia/reperfusion injury in a rat middle cerebral artery occlusion stroke</span></p>
<p style="top:434.6pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">model. J. Pineal Res. 37, 85</span><span style="font-family:AdvOT596495f2+20,serif;font-size:6.4pt;color:#2a7ca5">&#x2013;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">91</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">.</span></p>
<p style="top:442.6pt;left:306.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Pei, Z., Pang, S.F., Cheung, R.T., 2003. Administration of melatonin after onset of</span></p>
<p style="top:450.5pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">ischemia reduces the volume of cerebral infarction in a rat middle cerebral artery</span></p>
<p style="top:458.5pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">occlusion stroke model. Stroke 34, 770</span><span style="font-family:AdvOT596495f2+20,serif;font-size:6.4pt;color:#2a7ca5">&#x2013;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">775</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">.</span></p>
<p style="top:466.5pt;left:306.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Ramos, E., Pati&#xf1;o, P., Reiter, R.J., Gil-Martin, E., Marco-Contelles, J., Parada, E., de Los</span></p>
<p style="top:474.5pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Rios, C., Romero, A., Egea, J., 2017. Ischemic brain injury: new insights on the</span></p>
<p style="top:482.5pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">protective role of melatonin. Free Radic. Biol. Med. 104, 32</span><span style="font-family:AdvOT596495f2+20,serif;font-size:6.4pt;color:#2a7ca5">&#x2013;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">53</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">.</span></p>
<p style="top:490.4pt;left:306.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Reagan-Shaw, S., Nihal, M., Ahmad, N., 2008. Dose translation from animal to human</span></p>
<p style="top:498.4pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">studies revisited. FASEB J. 22, 659</span><span style="font-family:AdvOT596495f2+20,serif;font-size:6.4pt;color:#2a7ca5">&#x2013;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">661</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">.</span></p>
<p style="top:506.3pt;left:306.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Reiter, R.J., Richardson, B.A., Johnson, L.Y., Ferguson, B.N., Dinh, D.T., 1980. Pineal</span></p>
<p style="top:514.3pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">melatonin rhythm: reduction in aging Syrian hamsters. Science 210, 1372</span><span style="font-family:AdvOT596495f2+20,serif;font-size:6.4pt;color:#2a7ca5">&#x2013;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">1373</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">.</span></p>
<p style="top:522.3pt;left:306.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Reiter, R.J., Craft, C.M., Johnson Jr., J.E., King, T.S., Richardson, B.A., Vaughan, G.M.,</span></p>
<p style="top:530.3pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Vaughan, M.K., 1981. Age-associated reduction in nocturnal pineal melatonin levels</span></p>
<p style="top:538.2pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">in female rats. Endocrinology 109, 1295</span><span style="font-family:AdvOT596495f2+20,serif;font-size:6.4pt;color:#2a7ca5">&#x2013;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">1297</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">.</span></p>
<p style="top:546.2pt;left:306.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Reiter, R.J., Tan, D.X., Kim, S.J., Cruz, M.H., 2014. Delivery of pineal melatonin to the</span></p>
<p style="top:554.2pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">brain and SCN: role of canaliculi, cerebrospinal</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:6.4pt;color:#2a7ca5"> &#xfb02;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">uid, tanycytes and Virchow-Robin</span></p>
<p style="top:562.1pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">perivascular spaces. Brain Struct. Funct. 219, 1873</span><span style="font-family:AdvOT596495f2+20,serif;font-size:6.4pt;color:#2a7ca5">&#x2013;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">1887</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">.</span></p>
<p style="top:570.1pt;left:306.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Reiter, R.J., Ma, Q., Sharma, R., 2020. Melatonin in mitochondria: mitigating clear and</span></p>
<p style="top:578.1pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">present dangers. Physiology 35, 86</span><span style="font-family:AdvOT596495f2+20,serif;font-size:6.4pt;color:#2a7ca5">&#x2013;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">95</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">.</span></p>
<p style="top:586.0pt;left:306.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Revuelta, M., Arteaga, O., Montalvo, H., Alvarez, A., Hilario, E., Martinez-Ibarguen, A.,</span></p>
<p style="top:594.0pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">2016. Antioxidant treatments recover the alteration of auditory-evoked potentials</span></p>
<p style="top:602.0pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">and reduce morphological damage in the inferior colliculus after perinatal asphyxia</span></p>
<p style="top:610.0pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">in rat. Brain Pathol. 26, 186</span><span style="font-family:AdvOT596495f2+20,serif;font-size:6.4pt;color:#2a7ca5">&#x2013;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">198</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">.</span></p>
<p style="top:617.9pt;left:306.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Ritzenthaler, T., Nighoghossian, N., Berthiller, J., Schott, A.M., Cho, T.H., Derex, L., Brun,</span></p>
<p style="top:625.9pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">J., Trouillas, P., Claustrat, B., 2009. Nocturnal urine melatonin and 6-sulphatox-</span></p>
<p style="top:633.9pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">ymelatonin excretion at the acute stage of ischaemic stroke. J. Pineal Res. 46,</span></p>
<p style="top:641.8pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">349</span><span style="font-family:AdvOT596495f2+20,serif;font-size:6.4pt;color:#2a7ca5">&#x2013;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">352</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">.</span></p>
<p style="top:649.8pt;left:306.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Robertson, N.J., Faulkner, S., Fleiss, B., Bainbridge, A., Andorka, C., Price, D., Powell, E.,</span></p>
<p style="top:657.8pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Lecky-Thompson, L., Thei, L., Chandrasekaran, M., Hristova, M., Cady, E.B.,</span></p>
<p style="top:665.7pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Gressens, P., Golay, X., Raivich, G., 2013. Melatonin augments hypothermic neuro-</span></p>
<p style="top:673.7pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">protection in a perinatal asphyxia model. Brain 136, 90</span><span style="font-family:AdvOT596495f2+20,serif;font-size:6.4pt;color:#2a7ca5">&#x2013;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">105</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">.</span></p>
<p style="top:681.7pt;left:306.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Seabra, M.L., Bignotto, M., Pinto Jr., L.R., Tu</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:6.4pt;color:#2a7ca5">&#xfb01;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">k, S., 2000. Randomized, double-blind</span></p>
<p style="top:689.7pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">clinical trial, controlled with placebo, of the toxicology of chronic melatonin treat-</span></p>
<p style="top:697.6pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">ment. J. Pineal Res. 29, 193</span><span style="font-family:AdvOT596495f2+20,serif;font-size:6.4pt;color:#2a7ca5">&#x2013;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">200</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">.</span></p>
<p style="top:705.6pt;left:306.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Seron-Ferre, M., Torres-Farfan, C., Forcelledo, M.L., Valenzuela, G.J., 2001. The devel-</span></p>
<p style="top:713.5pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">opment of circadian rhythms in the fetus and neonate. Semin. Perinatol. 25, 363</span><span style="font-family:AdvOT596495f2+20,serif;font-size:6.4pt;color:#2a7ca5">&#x2013;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">370</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">.</span></p>
<p style="top:721.5pt;left:306.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Signorini, C., Ciccoli, L., Leoncini, S., Carloni, S., Perrone, S., Comporti, M., Balduini, W.,</span></p>
<p style="top:729.5pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Buonocore, G., 2009. Free iron, total F-isoprostanes and total F-neuroprostanes in a</span></p>
<p style="top:737.5pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">model of neonatal hypoxic-ischemic encephalopathy: neuroprotective e</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:6.4pt;color:#2a7ca5">&#xfb00;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">ect of</span></p>
<p style="top:36.8pt;left:37.6pt;line-height:6.4pt"><span style="font-family:AdvOT7fb33346.I,serif;font-size:6.4pt">E. Ramos, et al.</span></p>
<p style="top:36.8pt;left:397.5pt;line-height:6.4pt"><i><span style="font-family:CharisSIL,serif;font-size:6.4pt">Toxicology and Applied Pharm</span></i></p>
<p style="top:36.8pt;left:480.1pt;line-height:6.4pt"><i><span style="font-family:CharisSIL,serif;font-size:6.4pt">acology 392 (2020) 114933</span></i></p>
<p style="top:760.9pt;left:295.8pt;line-height:6.4pt"><span style="font-family:CharisSIL,serif;font-size:6.4pt">7</span></p>


<p style="top:60.0pt;left:49.5pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">melatonin. J. Pineal Res. 46, 148</span><span style="font-family:AdvOT596495f2+20,serif;font-size:6.4pt;color:#2a7ca5">&#x2013;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">154</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">.</span></p>
<p style="top:68.0pt;left:37.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Sinha, K., Degaonkar, M.N., Jagannathan, N.R., Gupta, Y.K., 2001. E</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:6.4pt;color:#2a7ca5">&#xfb00;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">ect of melatonin on</span></p>
<p style="top:76.0pt;left:49.5pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">ischemia reperfusion injury induced by middle cerebral artery occlusion in rats. Eur.</span></p>
<p style="top:83.9pt;left:49.5pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">J. Pharmacol. 428, 185</span><span style="font-family:AdvOT596495f2+20,serif;font-size:6.4pt;color:#2a7ca5">&#x2013;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">192</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">.</span></p>
<p style="top:91.9pt;left:37.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Tan, D.X., Reiter, R.J., 2019. Mitochondria: the birth place, battle ground and the site of</span></p>
<p style="top:99.8pt;left:49.5pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">melatonin metabolism in cells. Melatonin Res. 2, 44</span><span style="font-family:AdvOT596495f2+20,serif;font-size:6.4pt;color:#2a7ca5">&#x2013;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">66</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">.</span></p>
<p style="top:107.8pt;left:37.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Tang, Y., Cai, B., Yuan, F., He, X., Lin, X., Wang, J., Wang, Y., Yang, G.Y., 2014. Melatonin</span></p>
<p style="top:115.8pt;left:49.5pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Pretreatment improves the survival and function of transplanted mesenchymal stem</span></p>
<p style="top:123.8pt;left:49.5pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">cells after focal cerebral ischemia. Cell Transplant. 23, 1279</span><span style="font-family:AdvOT596495f2+20,serif;font-size:6.4pt;color:#2a7ca5">&#x2013;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">1291</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">.</span></p>
<p style="top:131.8pt;left:37.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Torii, K., Uneyama, H., Nishino, H., Kondoh, T., 2004. Melatonin suppresses cerebral</span></p>
<p style="top:139.7pt;left:49.5pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">edema caused by middle cerebral artery occlusion/reperfusion in rats assessed by</span></p>
<p style="top:147.7pt;left:49.5pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">magnetic resonance imaging. J. Pineal Res. 36, 18</span><span style="font-family:AdvOT596495f2+20,serif;font-size:6.4pt;color:#2a7ca5">&#x2013;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">24</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">.</span></p>
<p style="top:155.7pt;left:37.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Tutunculer, F., Eskiocak, S., Basaran, U.N., Ekuklu, G., Ayvaz, S., Vatansever, U., 2005.</span></p>
<p style="top:163.6pt;left:49.5pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">The protective role of melatonin in experimental hypoxic brain damage. Pediatr. Int.</span></p>
<p style="top:171.6pt;left:49.5pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">47, 434</span><span style="font-family:AdvOT596495f2+20,serif;font-size:6.4pt;color:#2a7ca5">&#x2013;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">439</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">.</span></p>
<p style="top:179.5pt;left:37.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Uz, T., Giusti, P., Franceschini, D., Kharlamov, A., Manev, H., 1996. Protective e</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:6.4pt;color:#2a7ca5">&#xfb00;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">ect of</span></p>
<p style="top:187.5pt;left:49.5pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">melatonin against hippocampal DNA damage induced by intraperitoneal adminis-</span></p>
<p style="top:195.5pt;left:49.5pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">tration of kainate to rats. Neuroscience 73, 631</span><span style="font-family:AdvOT596495f2+20,serif;font-size:6.4pt;color:#2a7ca5">&#x2013;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">636</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">.</span></p>
<p style="top:60.0pt;left:306.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Villapol, S., Fau, S., Renolleau, S., Biran, V., Charriaut-Marlangue, C., Baud, O., 2011.</span></p>
<p style="top:68.0pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Melatonin promotes myelination by decreasing white matter in</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:6.4pt;color:#2a7ca5">&#xfb02;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">ammation after</span></p>
<p style="top:76.0pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">neonatal stroke. Pediatr. Res. 69, 51</span><span style="font-family:AdvOT596495f2+20,serif;font-size:6.4pt;color:#2a7ca5">&#x2013;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">55</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">.</span></p>
<p style="top:83.9pt;left:306.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Welin, A.K., Svedin, P., Lapatto, R., Sultan, B., Hagberg, H., Gressens, P., Kjellmer, I.,</span></p>
<p style="top:91.9pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Mallard, C., 2007. Melatonin reduces in</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:6.4pt;color:#2a7ca5">&#xfb02;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">ammation and cell death in white matter in</span></p>
<p style="top:99.8pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">the mid-gestation fetal sheep following umbilical cord occlusion. Pediatr. Res. 61,</span></p>
<p style="top:107.8pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">153</span><span style="font-family:AdvOT596495f2+20,serif;font-size:6.4pt;color:#2a7ca5">&#x2013;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">158</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">.</span></p>
<p style="top:115.8pt;left:306.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Yang, Y., Jiang, S., Dong, Y., Fan, C., Zhao, L., Yang, X., Li, J., Di, S., Yue, L., Liang, G.,</span></p>
<p style="top:123.8pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Reiter, R.J., Qu, Y., 2015. Melatonin prevents cell death and mitochondrial dys-</span></p>
<p style="top:131.8pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">function via a SIRT1-dependent mechanism during ischemic-stroke in mice. J. Pineal</span></p>
<p style="top:139.7pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Res. 58, 61</span><span style="font-family:AdvOT596495f2+20,serif;font-size:6.4pt;color:#2a7ca5">&#x2013;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">70</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">.</span></p>
<p style="top:147.7pt;left:306.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Zhao, Z., Lu, C., Li, T., Wang, W., Ye, W., Zeng, R., Ni, L., Lai, Z., Wang, X., Liu, C., 2018.</span></p>
<p style="top:155.7pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">The protective e</span><span style="font-family:AdvOT596495f2+fb,serif;font-size:6.4pt;color:#2a7ca5">&#xfb00;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">ect of melatonin on brain ischemia and reperfusion in rats and</span></p>
<p style="top:163.6pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">humans: in vivo assessment and a randomized controlled trial. J. Pineal Res. 65,</span></p>
<p style="top:171.6pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">e12521</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">.</span></p>
<p style="top:179.5pt;left:306.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">Zivin, J.A., Fisher, M., DeGirolami, U., Hemenway, C.C., Stashak, J.A., 1985. Tissue</span></p>
<p style="top:187.5pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">plasminogen activator reduces neurological damage after cerebral embolism. Science</span></p>
<p style="top:195.5pt;left:318.6pt;line-height:6.4pt"><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">230, 1289</span><span style="font-family:AdvOT596495f2+20,serif;font-size:6.4pt;color:#2a7ca5">&#x2013;</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt;color:#2a7ca5">1292</span><span style="font-family:AdvOT596495f2,serif;font-size:6.4pt">.</span></p>
<p style="top:36.8pt;left:37.6pt;line-height:6.4pt"><span style="font-family:AdvOT7fb33346.I,serif;font-size:6.4pt">E. Ramos, et al.</span></p>
<p style="top:36.8pt;left:397.5pt;line-height:6.4pt"><i><span style="font-family:CharisSIL,serif;font-size:6.4pt">Toxicology and Applied Pharm</span></i></p>
<p style="top:36.8pt;left:480.1pt;line-height:6.4pt"><i><span style="font-family:CharisSIL,serif;font-size:6.4pt">acology 392 (2020) 114933</span></i></p>
<p style="top:760.9pt;left:295.8pt;line-height:6.4pt"><span style="font-family:CharisSIL,serif;font-size:6.4pt">8</span></p>

</div>
